| Lactobacillus paracasei (case)i 431 |
For daily immunity |
Oral Administration of Probiotics Increases Paneth Cells and Intestinal Antimicrobial Activity. |
| Lactobacillus paracasei (case)i 431 |
For daily immunity |
Prospective study of probiotic supplementation results in immune stimulation and improvement of upper respiratory infection rate. |
| Aspergillus oryzae NK |
strong wakamoto w |
Antioxidant activity of a medicine based on Aspergillus oryzae NK koji measured by a modified t-butyl peroxyl radical scavenging assay. |
| Bacillus clausii N/R |
Enterogermina |
<i>Bacillus clausii</i> as adjunctive treatment for acute community-acquired diarrhea among Filipino children: a large-scale, multicenter, open-label study (CODDLE). |
| Bacillus clausii N/R |
Enterogermina |
Characterization of two Bacillus probiotics. |
| Bacillus clausii N/R |
Enterogermina |
Efficacy and safety of Bacillus clausii (O/C, N/R, SIN, T) probiotic combined with oral rehydration therapy (ORT) and zinc in acute diarrhea in children: a randomized, double-blind, placebo-controlled study in India. |
| Bacillus clausii N/R |
Enterogermina |
Kinetics of Intestinal Presence of Spores Following Oral Administration of Bacillus clausii Formulations: Three Single-Centre, Crossover, Randomised, Open-Label Studies. |
| Bacillus clausii N/R |
Enterogermina |
Molecular characterization and identification of Bacillus clausii Strains marketed for use in oral bacteriotherapy. |
| Bacillus clausii N/R |
Enterogermina |
Recommendations for the adjuvant use of the poly-antibiotic-resistant probiotic <i>Bacillus clausii</i> (O/C, SIN, N/R, T) in acute, chronic, and antibiotic-associated diarrhea in children: consensus from Asian experts. |
| Bacillus clausii N/R |
Enterogermina |
Results of treatment with Bacillus subtilis spores (Enterogermina) after antibiotic therapy in 95 patients with infection calculosis. |
| Bacillus clausii N/R |
Enterogermina |
The use of Bacillus subtilis as an antidiarrhoeal microorganism. |
| Bacillus clausii O/C |
Enterogermina |
<i>Bacillus clausii</i> as adjunctive treatment for acute community-acquired diarrhea among Filipino children: a large-scale, multicenter, open-label study (CODDLE). |
| Bacillus clausii O/C |
Enterogermina |
Characterization of two Bacillus probiotics. |
| Bacillus clausii O/C |
Enterogermina |
Efficacy and safety of Bacillus clausii (O/C, N/R, SIN, T) probiotic combined with oral rehydration therapy (ORT) and zinc in acute diarrhea in children: a randomized, double-blind, placebo-controlled study in India. |
| Bacillus clausii O/C |
Enterogermina |
Kinetics of Intestinal Presence of Spores Following Oral Administration of Bacillus clausii Formulations: Three Single-Centre, Crossover, Randomised, Open-Label Studies. |
| Bacillus clausii O/C |
Enterogermina |
Molecular characterization and identification of Bacillus clausii Strains marketed for use in oral bacteriotherapy. |
| Bacillus clausii O/C |
Enterogermina |
Recommendations for the adjuvant use of the poly-antibiotic-resistant probiotic <i>Bacillus clausii</i> (O/C, SIN, N/R, T) in acute, chronic, and antibiotic-associated diarrhea in children: consensus from Asian experts. |
| Bacillus clausii O/C |
Enterogermina |
Results of treatment with Bacillus subtilis spores (Enterogermina) after antibiotic therapy in 95 patients with infection calculosis. |
| Bacillus clausii O/C |
Enterogermina |
The use of Bacillus subtilis as an antidiarrhoeal microorganism. |
| Bacillus clausii SC-109 |
MegaSporebiotic |
Efficacy of Spore Forming Bacilli Supplementation in Patients with Mild to Moderate Elevation of Triglycerides: A 12 week, Randomized, Double-Blind, Placebo Controlled Trial. |
| Bacillus clausii SIN |
Enterogermina |
<i>Bacillus clausii</i> as adjunctive treatment for acute community-acquired diarrhea among Filipino children: a large-scale, multicenter, open-label study (CODDLE). |
| Bacillus clausii SIN |
Enterogermina |
Characterization of two Bacillus probiotics. |
| Bacillus clausii SIN |
Enterogermina |
Chromosomal aadD2 encodes an aminoglycoside nucleotidyltransferase in Bacillus clausii. |
| Bacillus clausii SIN |
Enterogermina |
Efficacy and safety of Bacillus clausii (O/C, N/R, SIN, T) probiotic combined with oral rehydration therapy (ORT) and zinc in acute diarrhea in children: a randomized, double-blind, placebo-controlled study in India. |
| Bacillus clausii SIN |
Enterogermina |
Kinetics of Intestinal Presence of Spores Following Oral Administration of Bacillus clausii Formulations: Three Single-Centre, Crossover, Randomised, Open-Label Studies. |
| Bacillus clausii SIN |
Enterogermina |
Molecular characterization and identification of Bacillus clausii Strains marketed for use in oral bacteriotherapy. |
| Bacillus clausii SIN |
Enterogermina |
Recommendations for the adjuvant use of the poly-antibiotic-resistant probiotic <i>Bacillus clausii</i> (O/C, SIN, N/R, T) in acute, chronic, and antibiotic-associated diarrhea in children: consensus from Asian experts. |
| Bacillus clausii SIN |
Enterogermina |
Results of treatment with Bacillus subtilis spores (Enterogermina) after antibiotic therapy in 95 patients with infection calculosis. |
| Bacillus clausii SIN |
Enterogermina |
Survival and persistence of Bacillus clausii in the human gastrointestinal tract following oral administration as spore-based probiotic formulation. |
| Bacillus clausii SIN |
Enterogermina |
The use of Bacillus subtilis as an antidiarrhoeal microorganism. |
| Bacillus clausii T |
Enterogermina |
Characterization of two Bacillus probiotics. |
| Bacillus clausii T |
Enterogermina |
Kinetics of Intestinal Presence of Spores Following Oral Administration of Bacillus clausii Formulations: Three Single-Centre, Crossover, Randomised, Open-Label Studies. |
| Bacillus clausii T |
Enterogermina |
Molecular characterization and identification of Bacillus clausii Strains marketed for use in oral bacteriotherapy. |
| Bacillus clausii T |
Enterogermina |
Results of treatment with Bacillus subtilis spores (Enterogermina) after antibiotic therapy in 95 patients with infection calculosis. |
| Bacillus clausii T |
Enterogermina |
The use of Bacillus subtilis as an antidiarrhoeal microorganism. |
| Bacillus coagulans GBI-30 |
Schiff® Digestive Advantage® Daily Probiotic |
Immunomodulation of antiretroviral drug-suppressed chronic HIV-1 infection in an oral probiotic double-blind placebo-controlled trial. |
| Bacillus coagulans GBI-30 |
Schiff® Digestive Advantage® Daily Probiotic |
Spores of Bacillus coagulans GBI-30, 6086 show high germination, survival and enzyme activity in a dynamic, computer-controlled in vitro model of the gastrointestinal tract. |
| Bacillus coagulans SC-208 |
MegaSporebiotic |
Efficacy of Spore Forming Bacilli Supplementation in Patients with Mild to Moderate Elevation of Triglycerides: A 12 week, Randomized, Double-Blind, Placebo Controlled Trial. |
| Bacillus coagulans SC208 |
Eded 3 in 1 |
Efficacy of Spore Forming Bacilli Supplementation in Patients with Mild to Moderate Elevation of Triglycerides: A 12 week, Randomized, Double-Blind, Placebo Controlled Trial. |
| Bacillus coagulans SC208 |
Eded 3 in 1 |
Treatment with a spore-based probiotic containing five strains of Bacillus induced changes in the metabolic activity and community composition of the gut microbiota in a SHIME® model of the human gastrointestinal system. |
| Bacillus indicus HU36 |
MegaSporebiotic |
Efficacy of Spore Forming Bacilli Supplementation in Patients with Mild to Moderate Elevation of Triglycerides: A 12 week, Randomized, Double-Blind, Placebo Controlled Trial. |
| Bacillus indicus HU36 |
MegaSporebiotic |
Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers. |
| Bacillus indicus HU36 |
MegaSporebiotic |
Treatment with a spore-based probiotic containing five strains of Bacillus induced changes in the metabolic activity and community composition of the gut microbiota in a SHIME® model of the human gastrointestinal system. |
| Bacillus mesentericus (subtilis) TO-A |
AOR, Probiotic 3 |
Novel Probiotic Mechanisms of the Oral Bacterium Streptococcus sp. A12 as Explored with Functional Genomics. |
| Bacillus mesentericus (subtilis) TO-A |
AOR, Probiotic 3 |
Oral Administration of Probiotic Enterococcus durans to Ameliorate Experimental Autoimmune Encephalomyelitis in Mice. |
| Bacillus mesentericus (subtilis) TO-A |
AOR, Probiotic 3 |
Oral probiotics influence oral and respiratory tract infections in pediatric population: a randomized double-blinded placebo-controlled pilot study. |
| Bacillus mesentericus (subtilis) TO-A |
AOR, Probiotic 3 |
Orally Administered Probiotics in the Prevention of Chemotherapy (± Radiotherapy)-Induced Gastrointestinal Toxicity: A Systematic Review With Meta-Analysis of Randomized Trials. |
| Bacillus mesentericus (subtilis) TO-A |
AOR, Probiotic 3 |
Orally Ingested Probiotic, Prebiotic, and Synbiotic Interventions as Countermeasures for Gastrointestinal Tract Infections in Nonelderly Adults: A Systematic Review and Meta-Analysis. |
| Bacillus mesentericus (subtilis) TO-A |
AOR, Probiotic 3 |
Polyphenols Content and In Vitro a-Glycosidase Activity of Different Italian Monofloral Honeys, and Their Effect on Selected Pathogenic and Probiotic Bacteria. |
| Bacillus mesentericus (subtilis) TO-A |
AOR, Probiotic 3 |
Probiotic lactobacilli in breast milk and infant stool in relation to oral intake during the first year of life. |
| Bacillus subtilis DE111 |
Probiotic w/ DE111 |
Acute physiological effects following Bacillus subtilis DE111 oral ingestion - a randomised, double blinded, placebo-controlled study. |
| Bacillus Subtilis HU58 |
MegaSporebiotic |
An Oral Formulation of the Probiotic, <i>Bacillus subtilis</i> HU58, Was Safe and Well Tolerated in a Pilot Study of Patients with Hepatic Encephalopathy. |
| Bacillus Subtilis HU58 |
MegaSporebiotic |
Efficacy of Spore Forming Bacilli Supplementation in Patients with Mild to Moderate Elevation of Triglycerides: A 12 week, Randomized, Double-Blind, Placebo Controlled Trial. |
| Bacillus Subtilis HU58 |
MegaSporebiotic |
Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers. |
| Bacillus Subtilis HU58 |
MegaSporebiotic |
Treatment with a spore-based probiotic containing five strains of Bacillus induced changes in the metabolic activity and community composition of the gut microbiota in a SHIME® model of the human gastrointestinal system. |
| Bacteroides xylanisolvens DSM 23964 |
AVI-1 (pending on market) |
Impact of oral consumption of heat-treated Bacteroides xylanisolvens DSM 23964 on the level of natural TFa-specific antibodies in human adults. |
| Bacteroides xylanisolvens DSM 23964 |
AVI-1 (pending on market) |
Safety and tolerance of Bacteroides xylanisolvens DSM 23964 in healthy adults. |
| Bacteroides xylanisolvens DSM 23964 |
AVI-1 (pending on market) |
Safety assessment of the commensal strain Bacteroides xylanisolvens DSM 23964. |
| Bifidobacterium animalis ssp. lactis 420 |
UltraFlora® Control |
Effects of Bifidobacterium animalis ssp. lactis 420 on gastrointestinal inflammation induced by a non-steroidal anti-inflammatory drug: a randomized, placebo-controlled, double-blind clinical trial. |
| Bifidobacterium animalis ssp. lactis 420 |
UltraFlora® Control |
Efficacy of Fish Oil and/or Probiotic Intervention on the Incidence of Gestational Diabetes Mellitus in an At-Risk Group of Overweight and Obese Women: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial. |
| Bifidobacterium animalis ssp. lactis 420 |
UltraFlora® Control |
Linking bacterial tetrabromopyrrole biosynthesis to coral metamorphosis. |
| Bifidobacterium animalis ssp. lactis 420 |
UltraFlora® Control |
Probiotic B420 and prebiotic polydextrose improve efficacy of antidiabetic drugs in mice. |
| Bifidobacterium animalis ssp. lactis 420 |
UltraFlora® Control |
Temporal stability and community assembly mechanisms in healthy broiler cecum. |
| Bifidobacterium animalis ssp. lactis 420 |
UltraFlora® Control |
Weight gain and body composition during pregnancy: a randomised pilot trial with probiotics and/or fish oil. |
| Bifidobacterium animalis subsp lactis HN019 |
Optibac Every Day Max |
Acute oral toxicity and bacterial translocation studies on potentially probiotic strains of lactic acid bacteria. |
| Bifidobacterium animalis subsp lactis HN019 |
Optibac Every Day Max |
Benefits of Bifidobacterium animalis subsp. lactis Probiotic in Experimental Periodontitis. |
| Bifidobacterium animalis subsp lactis HN019 |
Optibac Every Day Max |
Bifidobacterium animalis subsp lactis HN019 presents antimicrobial potential against periodontopathogens and modulates the immunological response of oral mucosa in periodontitis patients. |
| Bifidobacterium animalis subsp lactis HN019 |
Optibac Every Day Max |
Dietary Bifidobacterium lactis (HN019) enhances resistance to oral Salmonella typhimurium infection in mice. |
| Bifidobacterium animalis subsp lactis HN019 |
Optibac Every Day Max |
Effects of oral administration of Bifidobacterium animalis subsp. lactis HN019 on the treatment of plaque-induced generalized gingivitis. |
| Bifidobacterium animalis subsp lactis HN019 |
Optibac Every Day Max |
Use of the Probiotic Bifidobacterium animalis subsp. lactis HN019 in Oral Diseases. |
| Bifidobacterium animalis subsp. lactis CECT 8145 |
Culturelle Healthy Metabolism + Weight Management Supplement |
Anti-obesity properties of the strain Bifidobacterium animalis subsp. lactis CECT 8145 in Zücker fatty rats. |
| Bifidobacterium animalis subsp. lactis CECT 8145 |
Culturelle Healthy Metabolism + Weight Management Supplement |
Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial. |
| Bifidobacterium bifidum G9-1 (BBG9-1) |
Phillips'® Colon Health |
Effects of Bifidobacterium bifidum G9-1 on Nasal Symptoms in a Guinea Pig Model of Experimental Allergic Rhinitis. |
| Bifidobacterium bifidum G9-1 (BBG9-1) |
Phillips'® Colon Health |
Longitudinal study of effects of oral dosage of Bifidobacterium bifidum G9-1 on Japanese cedar pollen-induced allergic nasal symptoms in guinea pigs. |
| Bifidobacterium bifidum G9-1 (BBG9-1) |
Phillips'® Colon Health |
Oral administration of Bifidobacterium bifidum G9-1 alleviates rotavirus gastroenteritis through regulation of intestinal homeostasis by inducing mucosal protective factors. |
| Bifidobacterium bifidum G9-1 (BBG9-1) |
Phillips'® Colon Health |
Oral administration of Bifidobacterium bifidum G9-1 suppresses total and antigen specific immunoglobulin E production in mice. |
| Bifidobacterium bifidum G9-1 (BBG9-1) |
Phillips'® Colon Health |
Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. |
| Bifidobacterium bifidum G9-1 (BBG9-1) |
Phillips'® Colon Health |
The protective effect of <i>Bifidobacterium bifidum</i> G9-1 against mucus degradation by <i>Akkermansia muciniphila</i> following small intestine injury caused by a proton pump inhibitor and aspirin. |
| Bifidobacterium breve M-16V |
Optibac Probiotics Professional |
A Specific Mixture of Fructo-Oligosaccharides and Bifidobacterium breve M-16V Facilitates Partial Non-Responsiveness to Whey Protein in Mice Orally Exposed to ß-Lactoglobulin-Derived Peptides. |
| Bifidobacterium breve M-16V |
Optibac Probiotics Professional |
Cow milk allergy symptoms are reduced in mice fed dietary synbiotics during oral sensitization with whey. |
| Bifidobacterium breve M-16V |
Optibac Probiotics Professional |
Effects of oral administration of bifidobacterium breve on fecal lactic acid and short-chain fatty acids in low birth weight infants. |
| Bifidobacterium breve M-16V |
Optibac Probiotics Professional |
Oral treatment with probiotics reduces allergic symptoms in ovalbumin-sensitized mice: a bacterial strain comparative study. |
| Bifidobacterium breve M-16V |
Optibac Probiotics Professional |
Probiotics for Irritable Bowel Syndrome: Clinical Data in Children. |
| Bifidobacterium breve M-16V |
Optibac Probiotics Professional |
Safety evaluation of probiotic bifidobacteria by analysis of mucin degradation activity and translocation ability. |
| Bifidobacterium breve M-16V |
Optibac Probiotics Professional |
Strain-Specific Probiotic Properties of Bifidobacteria and Lactobacilli for the Prevention of Diarrhea Caused by Rotavirus in a Preclinical Model. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Administration of Bifidobacterium animalis subsp. lactis BB-12 in early childhood: a post-trial effect on caries occurrence at four years of age. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Bacteriological effects of a Lactobacillus reuteri probiotic on in vitro oral biofilms. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Bifidobacterium animalis subsp. lactis BB-12 administration in early childhood: a randomized clinical trial of effects on oral colonization by mutans streptococci and the probiotic. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Effect of Lactobacillus rhamnosus and Bifidobacterium lactis on gingival health, dental plaque, and periodontopathogens in adolescents: a randomised placebo-controlled clinical trial. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Effect of Probiotic Containing Ice-cream on Salivary Mutans Streptococci (SMS) Levels in Children of 6-12 Years of Age: A Randomized Controlled Double Blind Study with Six-months Follow Up. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Effect of Probiotic Use on Antibiotic Administration Among Care Home Residents: A Randomized Clinical Trial. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Faecal SIgA secretion in infants fed on pre- or probiotic infant formula. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Human Gut Microbiome Response Induced by Fermented Dairy Product Intake in Healthy Volunteers. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Impact of orally administered lozenges with Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12 on the number of salivary mutans streptococci, amount of plaque, gingival inflammation and the oral microbiome in healthy adults. |
| Bifidobacterium lactis BB-12 |
Nestlé |
In vitro removal of polycyclic aromatic hydrocarbons by lactic acid bacteria. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Prebiotic activity of monofloral honeys produced by stingless bees in the semi-arid region of Brazilian Northeastern toward Lactobacillus acidophilus LA-05 and Bifidobacterium lactis BB-12. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Probiotic effects on 5-fluorouracil-induced mucositis assessed by the sucrose breath test in rats. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Probiotic intervention influences the salivary levels of Matrix Metalloproteinase (MMP)-9 and Tissue Inhibitor of metalloproteinases (TIMP)-1 in healthy adults. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Probiotic-induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory-dependent mechanisms in a murine model of asthma. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Protocol for a double-blind placebo-controlled trial to evaluate the efficacy of probiotics in reducing antibiotics for infection in care home residents: the Probiotics to Reduce Infections iN CarE home reSidentS (PRINCESS) trial. |
| Bifidobacterium lactis BB-12 |
Nestlé |
Tetracycline susceptibility of the ingested Lactobacillus acidophilus LaCH-5 and Bifidobacterium animalis subsp. lactis Bb-12 strains during antibiotic/probiotic intervention. |
| Bifidobacterium lactis BB-12 |
Nestlé |
The effect of probiotic bacteria (Lactobacillus acidophilus and Bifidobacterium lactis) on the accumulation of lead in rat brains. |
| Bifidobacterium lactis Bi-07 |
UltraFlora® Balance |
A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO). |
| Bifidobacterium lactis Bi-07 |
UltraFlora® Balance |
Fermented milk supplemented with probiotics and prebiotics can effectively alter the intestinal microbiota and immunity of host animals. |
| Bifidobacterium lactis Bi-07 |
UltraFlora® Balance |
Metal-Phenolic Network Directed Coating of Single Probiotic Cell Followed by Photoinitiated Thiol-Ene Click Fortification to Enhance Oral Therapy. |
| Bifidobacterium lactis Bi-07 |
UltraFlora® Balance |
Oral administration of fermented milk supplemented with synbiotics can influence the physiological condition of Wistar rats in a dose-sensitive and sex-specific manner. |
| Bifidobacterium lactis Bi-07 |
UltraFlora® Balance |
Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection. |
| Bifidobacterium lactis Bi-07 |
UltraFlora® Balance |
Probiotic Bifidobacterium animalis subsp. lactis Bi-07 alleviates bacterial translocation and ameliorates microinflammation in experimental uraemia. |
| Bifidobacterium lactis Bi-07 |
UltraFlora® Balance |
Safety evaluation of HOWARU<sup>®</sup> Restore (Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium animalis subsp. lactis Bl-04 and B. lactis Bi-07) for antibiotic resistance, genomic risk factors, and acute toxicity. |
| Bifidobacterium lactis Bl-04 |
Optibac Probiotics Every Day MAX Probiotics |
A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO). |
| Bifidobacterium lactis Bl-04 |
Optibac Probiotics Every Day MAX Probiotics |
Effects of a nine-strain bacterial synbiotic compared to simethicone in colicky babies - an open-label randomised study. |
| Bifidobacterium lactis Bl-04 |
Optibac Probiotics Every Day MAX Probiotics |
Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. |
| Bifidobacterium lactis Bl-04 |
Optibac Probiotics Every Day MAX Probiotics |
First evaluation of a symbiotic food supplement in an allergen exposure chamber in birch pollen allergic patients. |
| Bifidobacterium lactis Bl-04 |
Optibac Probiotics Every Day MAX Probiotics |
Safety evaluation of HOWARU<sup>®</sup> Restore (Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium animalis subsp. lactis Bl-04 and B. lactis Bi-07) for antibiotic resistance, genomic risk factors, and acute toxicity. |
| Bifidobacterium longum 1714 |
Zenflore® |
Psychobiotics: Shaping the Mind With Gut Bacteria. |
| Bifidobacterium longum 35624 |
Align |
An Exopolysaccharide Produced by Bifidobacterium longum 35624® Inhibits Osteoclast Formation via a TLR2-Dependent Mechanism. |
| Bifidobacterium longum 35624 |
Align |
Probiotic treatment (Bifidobacterium longum subsp. longum 35624™) affects stress responsivity in male rats after chronic corticosterone exposure. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Anti-obesity properties of the strain Bifidobacterium animalis subsp. lactis CECT 8145 in Zücker fatty rats. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Clinical efficacy of probiotic Bifidobacterium longum for the treatment of symptoms of Japanese cedar pollen allergy in subjects evaluated in an environmental exposure unit. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Effect of <i>Lactobacillus rhamnosus</i> HN001 and <i>Bifidobacterium longum</i> BB536 on the healthy gut microbiota composition at phyla and species level: A preliminary study. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Effect of repeated oral administration of Bifidobacterium longum BB536 on apomorphine-induced rearing behavior in mice. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Effect of the oral intake of yogurt containing Bifidobacterium longum BB536 on the cell numbers of enterotoxigenic Bacteroides fragilis in microbiota. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Efficacy of a mixture of probiotic agents as complementary therapy for chronic functional constipation in childhood. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Modulation of T Regulatory and Dendritic Cell Phenotypes Following Ingestion of <i>Bifidobacterium longum</i>, AHCC<sup>®</sup> and Azithromycin in Healthy Individuals. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Oral administration of an immunostimulatory DNA sequence from Bifidobacterium longum improves Th1/Th2 balance in a murine model. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Oral administration of Bifidobacterium longum ameliorates influenza virus infection in mice. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Oral administration of Bifidobacterium longum prevents gut-derived Pseudomonas aeruginosa sepsis in mice. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Perioperative supplementation with bifidobacteria improves postoperative nutritional recovery, inflammatory response, and fecal microbiota in patients undergoing colorectal surgery: a prospective, randomized clinical trial. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Prevention of heterocyclic amine-induced DNA damage in colon and liver of rats by different lactobacillus strains. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Probiotics for Irritable Bowel Syndrome: Clinical Data in Children. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Safety evaluation of Bifidobacterium pseudocatenulatum G4 as assessed in BALB/c mice. |
| Bifidobacterium longum BB536 |
Probiotic Pro Bb536 |
Safety evaluation of probiotic bifidobacteria by analysis of mucin degradation activity and translocation ability. |
| Bifidobacterium longum ES1 |
PharmExtracta / Gliadines buccal stickpacks |
Early Oral Administration of Ginseng Stem-Leaf Saponins Enhances the Peyer`s Patch-Dependent Maternal IgA Antibody Response to a PEDV Inactivated Vaccine in Mice, with Gut Microbiota Involvement. |
| Bifidobacterium longum ES1 |
PharmExtracta / Gliadines buccal stickpacks |
Looking for Possible Benefits of Combining Short-Chain Fructo-Oligosaccharides (scFOS) with Saccharomyces cerevisiae Sc 47 on Weaned Pigs Orally Challenged with Escherichia coli F4(). |
| Bifidobacterium longum ES1 |
PharmExtracta / Gliadines buccal stickpacks |
Metal-Phenolic Network Directed Coating of Single Probiotic Cell Followed by Photoinitiated Thiol-Ene Click Fortification to Enhance Oral Therapy. |
| Bifidobacterium longum MM-2 |
Phillips'® Colon Health |
Consecutive oral administration of Bifidobacterium longum MM-2 improves the defense system against influenza virus infection by enhancing natural killer cell activity in a murine model. |
| Bifidobacterium longum R0175 |
Calm Biotic® |
Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. |
| Bifidobacterium longum R0175 |
Calm Biotic® |
Beneficial modulation of human health in the oral cavity and beyond using bacteriocin-like inhibitory substance-producing streptococcal probiotics. |
| Bifidobacterium longum R0175 |
Calm Biotic® |
Bifidobacterium longum R0175 attenuates post-myocardial infarction depressive-like behaviour in rats. |
| Bifidobacterium longum R0175 |
Calm Biotic® |
Bifidobacterium longum R0175 Protects Rats against d-Galactosamine-Induced Acute Liver Failure. |
| Bifidobacterium longum R0175 |
Calm Biotic® |
Chronic administration of a microencapsulated probiotic enhances the bioavailability of orange juice flavanones in humans. |
| Bifidobacterium longum R0175 |
Calm Biotic® |
Combination of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 reduces post-myocardial infarction depression symptoms and restores intestinal permeability in a rat model. |
| Bifidobacterium longum R0175 |
Calm Biotic® |
Effects of a nine-strain bacterial synbiotic compared to simethicone in colicky babies - an open-label randomised study. |
| Bifidobacterium longum R0175 |
Calm Biotic® |
Ingestion of probiotic (Lactobacillus helveticus and Bifidobacterium longum) alters intestinal microbial structure and behavioral expression following social defeat stress. |
| Bifidobacterium longum R0175 |
Calm Biotic® |
Oral Probiotics Ameliorate the Behavioral Deficits Induced by Chronic Mild Stress in Mice via the Gut Microbiota-Inflammation Axis. |
| Bifidobacterium longum R0175 |
Calm Biotic® |
The Effects of Probiotic Formulation Pretreatment (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) on a Lipopolysaccharide Rat Model. |
| Bifidobacterium longum ssp. infantis R0033 |
Human Probiotics |
Effect of probiotics on digestibility and immunity in infants: A study protocol for a randomized controlled trial. |
| Bifidobacterium longum subsp. infantis NLS |
Life Start 2 |
Bifidobacterium infantis NLS Super Strain Reduces the Expression of a-Defensin-5, a Marker of Innate Immunity, in the Mucosa of Active Celiac Disease Patients. |
| Bifidobacterium longum W11 |
PharmExtracta / Bowell |
Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir fos (Bifidobacterium longum W11 + FOS Actilight). |
| Clostridium Butyricum MIYAIRI |
Miyarisan |
[Intestinal Care Using L?Glutamine Supplement and Probiotics Can Induce a Strong Anti?Tumor Immune Response through the Induction of Mature Tertiary Lymphoid Structures in Pancreatic Cancer Patients Receiving Preoperative Chemotherapy]. |
| Clostridium Butyricum MIYAIRI |
Miyarisan |
Cholesterol-lowering effect of Clostridium butyricum in cholesterol-fed rats. |
| Clostridium Butyricum MIYAIRI |
Miyarisan |
Effect of Clostridium butyricum on the formation and dissolution of gallstones in experimental cholesterol cholelithiasis. |
| Clostridium Butyricum MIYAIRI |
Miyarisan |
Effects of orally administered Clostridium butyricum MIYAIRI 588 on mucosal immunity in mice. |
| Clostridium Butyricum MIYAIRI |
Miyarisan |
Establishment of an Endogenous <i>Clostridium difficile</i> Rat Infection Model and Evaluation of the Effects of <i>Clostridium butyricum</i> MIYAIRI 588 Probiotic Strain. |
| Clostridium Butyricum MIYAIRI |
Miyarisan |
Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats. |
| Clostridium Butyricum MIYAIRI |
Miyarisan |
The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis. |
| Clostridium Butyricum MIYAIRI |
Miyarisan |
The impact of Clostridium butyricum MIYAIRI 588 on the murine gut microbiome and colonic tissue. |
| Clostridium Butyricum MIYAIRI |
Miyarisan |
The impact of probiotic Clostridium butyricum MIYAIRI 588 on murine gut metabolic alterations. |
| Clostridium butyricum TO-A |
AOR, Probiotic 3 |
<i>Clostridium butyricum</i> CGMCC0313.1 Protects against Autoimmune Diabetes by Modulating Intestinal Immune Homeostasis and Inducing Pancreatic Regulatory T Cells. |
| Clostridium butyricum TO-A |
AOR, Probiotic 3 |
[Intestinal Care Using L?Glutamine Supplement and Probiotics Can Induce a Strong Anti?Tumor Immune Response through the Induction of Mature Tertiary Lymphoid Structures in Pancreatic Cancer Patients Receiving Preoperative Chemotherapy]. |
| Clostridium butyricum TO-A |
AOR, Probiotic 3 |
Development and validation of PCR primers to assess the diversity of Clostridium spp. in cheese by temporal temperature gradient gel electrophoresis. |
| Clostridium butyricum TO-A |
AOR, Probiotic 3 |
Oral administration of Clostridium butyricum rescues streptomycin-exacerbated respiratory syncytial virus-induced lung inflammation in mice. |
| Clostridium butyricum TO-A |
AOR, Probiotic 3 |
Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. |
| Enterococcus faecium L3 |
PharmExtracta / INatal Sachets |
Use of a probiotic mixture containing Bifidobacterium animalis subsp. lactis BB12 and Enterococcus faecium L3 in atopic children. |
| Enterococcus faecium SF 68 |
Bioflorin |
Are probiotics detectable in human feces after oral uptake by healthy volunteers? |
| Enterococcus faecium SF 68 |
Bioflorin |
Microbiological study of Enterococcus faecium SF68: post-antibiotic effect and growth curves. |
| Escherichia coli , Laves strain 1931 |
Colibiogen |
Cytokine production by mononuclear cells following stimulation with a peptide-containing, endotoxin-free Escherichia coli extract. |
| Heat Killed Lactobacillus plantarum L-137 |
Swanson Immunobiotic Immuno-LP20 |
Anti-inflammatory effects of heat-killed Lactobacillus plantarum L-137 on cardiac and adipose tissue in rats with metabolic syndrome. |
| Heat Killed Lactobacillus plantarum L-137 |
Swanson Immunobiotic Immuno-LP20 |
Daily Intake of Heat-killed Lactobacillus plantarum L-137 Decreases the Probing Depth in Patients Undergoing Supportive Periodontal Therapy. |
| Heat Killed Lactobacillus plantarum L-137 |
Swanson Immunobiotic Immuno-LP20 |
Daily intake of heat-killed Lactobacillus plantarum L-137 enhances type I interferon production in healthy humans and pigs. |
| Heat Killed Lactobacillus plantarum L-137 |
Swanson Immunobiotic Immuno-LP20 |
Lactobacillus plantarum L-137 upregulates hyaluronic acid production in epidermal cells and fibroblasts in mice. |
| Heat Killed Lactobacillus plantarum L-137 |
Swanson Immunobiotic Immuno-LP20 |
Oral administration of heat-killed Lactobacillus plantarum L-137 enhances protection against influenza virus infection by stimulation of type I interferon production in mice. |
| Heat Killed Lactobacillus plantarum L-137 |
Swanson Immunobiotic Immuno-LP20 |
Oral intake of heat-killed Lactobacillus plantarum L-137 decreases the incidence of upper respiratory tract infection in healthy subjects with high levels of psychological stress. |
| Lacticaseibacillus paracasei subsp. paracasei CNCM I-1518 |
DanActive |
Lactobacillus paracasei feeding improves immune control of influenza infection in mice. |
| Lacticaseibacillus paracasei subsp. paracasei CNCM I-1518 |
DanActive |
Lactobacillus paracasei feeding improves the control of secondary experimental meningococcal infection in flu-infected mice. |
| Lacticaseibacillus paracasei subsp. paracasei CNCM I-1518 |
DanActive |
Oral Administration of Probiotics Increases Paneth Cells and Intestinal Antimicrobial Activity. |
| Lacticaseibacillus rhamnosus HN001 |
Optibac Probiotics Babies & Children Probiotics |
A Healthy Vaginal Microbiota Remains Stable during Oral Probiotic Supplementation: A Randomised Controlled Trial. |
| Lacticaseibacillus rhamnosus HN001 |
Optibac Probiotics Babies & Children Probiotics |
Acute oral toxicity and bacterial translocation studies on potentially probiotic strains of lactic acid bacteria. |
| Lacticaseibacillus rhamnosus HN001 |
Optibac Probiotics Babies & Children Probiotics |
Effect of <i>Lactobacillus rhamnosus</i> HN001 and <i>Bifidobacterium longum</i> BB536 on the healthy gut microbiota composition at phyla and species level: A preliminary study. |
| Lacticaseibacillus rhamnosus HN001 |
Optibac Probiotics Babies & Children Probiotics |
EFFECT OF PROBIOTIC ORAL ADMINISTRATION ON SKIN WOUND HEALING IN RATS. |
| Lacticaseibacillus rhamnosus HN001 |
Optibac Probiotics Babies & Children Probiotics |
EFFECT OF SUPPLEMENTATION WITH PROBIOTICS ON COLONIC ANASTOMOSES IN RATS: MORPHOLOGICAL AND TENSIOMETRIC STUDY. |
| Lacticaseibacillus rhamnosus HN001 |
Optibac Probiotics Babies & Children Probiotics |
Effects of Bifidobacterium longum Subsp. infantis CECT 7210 and Lactobacillus rhamnosus HN001, Combined or Not With Oligofructose-Enriched Inulin, on Weaned Pigs Orally Challenged With Salmonella Typhimurium. |
| Lacticaseibacillus rhamnosus HN001 |
Optibac Probiotics Babies & Children Probiotics |
Efficacy of Fish Oil and/or Probiotic Intervention on the Incidence of Gestational Diabetes Mellitus in an At-Risk Group of Overweight and Obese Women: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial. |
| Lacticaseibacillus rhamnosus HN001 |
Optibac Probiotics Babies & Children Probiotics |
Immune enhancement conferred by oral delivery of Lactobacillus rhamnosus HN001 in different milk-based substrates. |
| Lacticaseibacillus rhamnosus HN001 |
Optibac Probiotics Babies & Children Probiotics |
Lactobacilli postbiotics reduce biofilm formation and alter transcription of virulence genes of Aggregatibacter actinomycetemcomitans. |
| Lacticaseibacillus rhamnosus HN001 |
Optibac Probiotics Babies & Children Probiotics |
Lactobacilli vaginal colonisation after oral consumption of Respecta(®) complex: a randomised controlled pilot study. |
| Lacticaseibacillus rhamnosus HN001 |
Optibac Probiotics Babies & Children Probiotics |
Probiotics and immunosenescence: cheese as a carrier. |
| Lacticaseibacillus rhamnosus HN001 |
Optibac Probiotics Babies & Children Probiotics |
Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. |
| Lacticaseibacillus rhamnosus HN001 |
Optibac Probiotics Babies & Children Probiotics |
Weight gain and body composition during pregnancy: a randomised pilot trial with probiotics and/or fish oil. |
| Lactobacillus acidophilus ATCC 4356 |
resB® Lung Support |
Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen. |
| Lactobacillus acidophilus ATCC 4356 |
resB® Lung Support |
Short communication: Modulation of the small intestinal microbial community composition over short-term or long-term administration with Lactobacillus plantarum ZDY2013. |
| Lactobacillus acidophilus CL1285 |
Bio-K+ |
Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. |
| Lactobacillus acidophilus CL1285 |
Bio-K+ |
Investigating the therapeutic potential of a probiotic in a clinical population with chronic hand dermatitis. |
| Lactobacillus acidophilus LA-14 |
Custom Probiotics |
Effects of a nine-strain bacterial synbiotic compared to simethicone in colicky babies - an open-label randomised study. |
| Lactobacillus acidophilus LA-14 |
Custom Probiotics |
Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. |
| Lactobacillus acidophilus LA-14 |
Custom Probiotics |
Lactobacilli vaginal colonisation after oral consumption of Respecta(®) complex: a randomised controlled pilot study. |
| Lactobacillus acidophilus LA-14 |
Custom Probiotics |
Recurrent bacterial symptomatic cystitis: A pilot study on a new natural option for treatment. |
| Lactobacillus Acidophilus LA1 |
Flora Pro Fem with Cranberry |
Combinatmarion treatment with Lactobacillus acidophilus LA-1, vitamin B, and curcumin ameliorates the progression of osteoarthritis by inhibiting the pro-inflammatory mediators. |
| Lactobacillus Acidophilus LA1 |
Flora Pro Fem with Cranberry |
Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. |
| Lactobacillus Acidophilus LA1 |
Flora Pro Fem with Cranberry |
Oral treatment with probiotic Lactobacillus johnsonii NCC533 (La1) for a specific part of the weaning period prevents the development of atopic dermatitis induced after maturation in model mice, NC/Nga. |
| Lactobacillus Acidophilus LA1 |
Flora Pro Fem with Cranberry |
Supplementation with oral probiotic bacteria maintains cutaneous immune homeostasis after UV exposure. |
| Lactobacillus Acidophilus LA1 |
Flora Pro Fem with Cranberry |
Supplementation with oral probiotic bacteria protects human cutaneous immune homeostasis after UV exposure-double blind, randomized, placebo controlled clinical trial. |
| Lactobacillus Acidophilus LA1 |
Flora Pro Fem with Cranberry |
The effect of probiotic supplementation on the risk of gestational diabetes mellitus among high-risk pregnant women: A parallel double-blind, randomized, placebo-controlled clinical trial. |
| Lactobacillus Acidophilus LA1 |
Flora Pro Fem with Cranberry |
Variable biotherapeutic effects of Lactobacillus acidophilus isolates on orogastric and systemic candidiasis in immunodeficient mice. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
A functional glycogen biosynthesis pathway in Lactobacillus acidophilus: expression and analysis of the glg operon. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO). |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Adjuvant treatment with a symbiotic in patients with inflammatory non-allergic rhinitis. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Cheese supplemented with probiotics reduced the Candida levels in denture wearers-RCT. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Dual functions of Lactobacillus acidophilus NCFM as protection against rotavirus diarrhea. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
EFFECT OF PROBIOTIC ORAL ADMINISTRATION ON SKIN WOUND HEALING IN RATS. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Effect of probiotics Lactobacillus acidophilus on Citrobacter rodentium colitis: the role of dendritic cells. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
EFFECT OF SUPPLEMENTATION WITH PROBIOTICS ON COLONIC ANASTOMOSES IN RATS: MORPHOLOGICAL AND TENSIOMETRIC STUDY. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Fermented milk supplemented with probiotics and prebiotics can effectively alter the intestinal microbiota and immunity of host animals. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
First evaluation of a symbiotic food supplement in an allergen exposure chamber in birch pollen allergic patients. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
High dose and low dose Lactobacillus acidophilus exerted differential immune modulating effects on T cell immune responses induced by an oral human rotavirus vaccine in gnotobiotic pigs. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Lactobacilli postbiotics reduce biofilm formation and alter transcription of virulence genes of Aggregatibacter actinomycetemcomitans. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Lipoteichoic acid-deficient Lactobacillus acidophilus regulates downstream signals. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Metal-Phenolic Network Directed Coating of Single Probiotic Cell Followed by Photoinitiated Thiol-Ene Click Fortification to Enhance Oral Therapy. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Nod2 is required for antigen-specific humoral responses against antigens orally delivered using a recombinant Lactobacillus vaccine platform. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Oral administration of fermented milk supplemented with synbiotics can influence the physiological condition of Wistar rats in a dose-sensitive and sex-specific manner. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Oral inoculation of probiotics Lactobacillus acidophilus NCFM suppresses tumour growth both in segmental orthotopic colon cancer and extra-intestinal tissue. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Probiotics and immunosenescence: cheese as a carrier. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Prophylactic feeding of Lactobacillus acidophilus NCFM to mice attenuates overt colonic hyperplasia. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Restoring specific lactobacilli levels decreases inflammation and muscle atrophy markers in an acute leukemia mouse model. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Safety evaluation of HOWARU<sup>®</sup> Restore (Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium animalis subsp. lactis Bl-04 and B. lactis Bi-07) for antibiotic resistance, genomic risk factors, and acute toxicity. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Strain-Specific Probiotic Properties of Bifidobacteria and Lactobacilli for the Prevention of Diarrhea Caused by Rotavirus in a Preclinical Model. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Temporal gene expression and probiotic attributes of Lactobacillus acidophilus during growth in milk. |
| Lactobacillus acidophilus NCFM |
UltraFlora® Balance |
Variable biotherapeutic effects of Lactobacillus acidophilus isolates on orogastric and systemic candidiasis in immunodeficient mice. |
| Lactobacillus acidophilus W37 |
Ecologic® Barrier for Metabolic Health |
Combined dietary supplementation of long chain inulin and Lactobacillus acidophilus W37 supports oral vaccination efficacy against Salmonella Typhimurium in piglets. |
| Lactobacillus casei LBC80R |
Bio-K+ |
Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. |
| Lactobacillus casei LBC80R |
Bio-K+ |
Investigating the therapeutic potential of a probiotic in a clinical population with chronic hand dermatitis. |
| Lactobacillus casei R0215 |
PharmExtracta / INatal Sachets |
Effects of a nine-strain bacterial synbiotic compared to simethicone in colicky babies - an open-label randomised study. |
| Lactobacillus casei Shirota |
Yakult |
[Intestinal Care Using L?Glutamine Supplement and Probiotics Can Induce a Strong Anti?Tumor Immune Response through the Induction of Mature Tertiary Lymphoid Structures in Pancreatic Cancer Patients Receiving Preoperative Chemotherapy]. |
| Lactobacillus casei Shirota |
Yakult |
[Prevention of irinotecan hydrochloride-induced diarrhea by oral administration of Lactobacillus casei strain Shirota in rats]. |
| Lactobacillus casei Shirota |
Yakult |
<i>Lactobacillus casei</i> Strain Shirota Enhances the In Vitro Antiproliferative Effect of Geniposide in Human Oral Squamous Carcinoma HSC-3 Cells. |
| Lactobacillus casei Shirota |
Yakult |
A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis. |
| Lactobacillus casei Shirota |
Yakult |
Antagonistic activity of Lactobacillus casei strain shirota against gastrointestinal Listeria monocytogenes infection in rats. |
| Lactobacillus casei Shirota |
Yakult |
Antiviral activity of Lactobacillus reuteri Protectis against Coxsackievirus A and Enterovirus 71 infection in human skeletal muscle and colon cell lines. |
| Lactobacillus casei Shirota |
Yakult |
Augmentation of cellular immunity and reduction of influenza virus titer in aged mice fed Lactobacillus casei strain Shirota. |
| Lactobacillus casei Shirota |
Yakult |
Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. |
| Lactobacillus casei Shirota |
Yakult |
Culture media for differential isolation of Lactobacillus casei Shirota from oral samples. |
| Lactobacillus casei Shirota |
Yakult |
Effect of <i>Lactobacillus casei</i> strain Shirota-fermented milk on metabolic abnormalities in obese prediabetic Japanese men: a randomised, double-blind, placebo-controlled trial. |
| Lactobacillus casei Shirota |
Yakult |
Effect of an oral administration of Lactobacillus casei strain Shirota on the natural killer activity of blood mononuclear cells in aged mice. |
| Lactobacillus casei Shirota |
Yakult |
Effect of Lactobacillus casei on the absorption of nifedipine from rat small intestine. |
| Lactobacillus casei Shirota |
Yakult |
Effect of probiotics, Bifidobacterium breve and Lactobacillus casei, on bisphenol A exposure in rats. |
| Lactobacillus casei Shirota |
Yakult |
Effects of <i>Lactobacillus casei</i> Shirota intake on caries risk in children. |
| Lactobacillus casei Shirota |
Yakult |
Effects of synbiotics on ileal microbiota. |
| Lactobacillus casei Shirota |
Yakult |
Enhanced antigen-specific delayed-type hypersensitivity and immunoglobulin G2b responses after oral administration of viable Lactobacillus casei YIT9029 in Wistar and Brown Norway rats. |
| Lactobacillus casei Shirota |
Yakult |
Enhanced immunological memory responses to Listeria monocytogenes in rodents, as measured by delayed-type hypersensitivity (DTH), adoptive transfer of DTH, and protective immunity, following Lactobacillus casei Shirota ingestion. |
| Lactobacillus casei Shirota |
Yakult |
Evaluation of immunomodulation by Lactobacillus casei Shirota: immune function, autoimmunity and gene expression. |
| Lactobacillus casei Shirota |
Yakult |
Immune effects of Lactobacillus casei Shirota in treated HIV-infected patients with poor CD4+ T-cell recovery. |
| Lactobacillus casei Shirota |
Yakult |
Immunomodulation by treatment with Lactobacillus casei strain Shirota. |
| Lactobacillus casei Shirota |
Yakult |
Immunomodulatory function of lactic acid bacteria. |
| Lactobacillus casei Shirota |
Yakult |
In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. |
| Lactobacillus casei Shirota |
Yakult |
In Vitro Evaluation of the Probiotic Potential of Halotolerant Lactobacilli Isolated from a Ripened Tropical Mexican Cheese. |
| Lactobacillus casei Shirota |
Yakult |
Inhibitory activity in vitro of probiotic lactobacilli against oral Candida under different fermentation conditions. |
| Lactobacillus casei Shirota |
Yakult |
Inhibitory effect of oral administration of Lactobacillus casei on 3-methylcholanthrene-induced carcinogenesis in mice. |
| Lactobacillus casei Shirota |
Yakult |
Injection of Lactobacillus casei strain Shirota affects autonomic nerve activities in a tissue-specific manner, and regulates glucose and lipid metabolism in rats. |
| Lactobacillus casei Shirota |
Yakult |
Intragastric administration of Lactobacillus casei expressing transmissible gastroentritis coronavirus spike glycoprotein induced specific antibody production. |
| Lactobacillus casei Shirota |
Yakult |
Lactic acid bacterium potently induces the production of interleukin-12 and interferon-gamma by mouse splenocytes. |
| Lactobacillus casei Shirota |
Yakult |
Lactobacillus casei Shirota does not decrease the food allergic response to peanut extract in Brown Norway rats. |
| Lactobacillus casei Shirota |
Yakult |
Lactobacillus casei Shirota enhances the preventive efficacy of soymilk in chemically induced breast cancer. |
| Lactobacillus casei Shirota |
Yakult |
Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. |
| Lactobacillus casei Shirota |
Yakult |
Lactobacillus rhamnosus GG induces tumor regression in mice bearing orthotopic bladder tumors. |
| Lactobacillus casei Shirota |
Yakult |
Microbial products from probiotic bacteria inhibit Salmonella enteritidis 857-induced IL-8 synthesis in Caco-2 cells. |
| Lactobacillus casei Shirota |
Yakult |
Modulating immune responses with probiotic bacteria. |
| Lactobacillus casei Shirota |
Yakult |
Oral administration of Lactobacillus casei Shirota can ameliorate the adverse effect of an acute aflatoxin exposure in Sprague Dawley rats. |
| Lactobacillus casei Shirota |
Yakult |
Oral administration of Lactobacillus casei Shirota improves recovery of hand functions after distal radius fracture among elder patients: a placebo-controlled, double-blind, and randomized trial. |
| Lactobacillus casei Shirota |
Yakult |
Oral administration of probiotic bacteria, Lactobacillus casei and Bifidobacterium breve, does not exacerbate neurological symptoms in experimental autoimmune encephalomyelitis. |
| Lactobacillus casei Shirota |
Yakult |
Oral Administration of Probiotic Lactobacillus Casei Shirota Decreases Pneumonia and Increases Pulmonary Functions after Single Rib Fracture: A Randomized Double-Blind, Placebo-Controlled Clinical Trial. |
| Lactobacillus casei Shirota |
Yakult |
Oral administration of probiotic Lactobacillus casei Shirota relieves pain after single rib fracture: a randomized double-blind, placebo-controlled clinical trial. |
| Lactobacillus casei Shirota |
Yakult |
Oral delivery of a probiotic induced changes at the nasal mucosa of seasonal allergic rhinitis subjects after local allergen challenge: a randomised clinical trial. |
| Lactobacillus casei Shirota |
Yakult |
Oral delivery of Lactobacillus casei Shirota modifies allergen-induced immune responses in allergic rhinitis. |
| Lactobacillus casei Shirota |
Yakult |
Probiotic <i>Lactobacillus casei Shirota</i> improves efficacy of amoxicillin-sulbactam against childhood fast breathing pneumonia in a randomized placebo-controlled double blind clinical study. |
| Lactobacillus casei Shirota |
Yakult |
Probiotic Lactobacillus casei Shirota supplementation does not modulate immunity in healthy men with reduced natural killer cell activity. |
| Lactobacillus casei Shirota |
Yakult |
Probiotic supplementation prevents high-fat, overfeeding-induced insulin resistance in human subjects. |
| Lactobacillus casei Shirota |
Yakult |
Probiotics and the urologist. |
| Lactobacillus casei Shirota |
Yakult |
Protective effect of Lactobacillus casei strain Shirota against lethal infection with multi-drug resistant Salmonella enterica serovar Typhimurium DT104 in mice. |
| Lactobacillus casei Shirota |
Yakult |
Randomized controlled study of probiotics containing Lactobacillus casei (Shirota strain) for prevention of ventilator-associated pneumonia. |
| Lactobacillus casei Shirota |
Yakult |
Reduction of aflatoxin level in aflatoxin-induced rats by the activity of probiotic Lactobacillus casei strain Shirota. |
| Lactobacillus casei Shirota |
Yakult |
Reduction of influenza virus titer and protection against influenza virus infection in infant mice fed Lactobacillus casei Shirota. |
| Lactobacillus casei Shirota |
Yakult |
Short communication: Effect of supplementation with Lactobacillus casei Shirota on insulin sensitivity, ß-cell function, and markers of endothelial function and inflammation in subjects with metabolic syndrome--a pilot study. |
| Lactobacillus casei Shirota |
Yakult |
Suppressive effects of the oral administration of Lactobacillus casei on type II collagen-induced arthritis in DBA/1 mice. |
| Lactobacillus casei Shirota |
Yakult |
The effect of a commercial probiotic drink containing Lactobacillus casei strain Shirota on oral health in healthy dentate people. |
| Lactobacillus casei Shirota |
Yakult |
The effect of a commercial probiotic drink on oral microbiota in healthy complete denture wearers. |
| Lactobacillus casei Shirota |
Yakult |
The effect of an oral administration of Lactobacillus casei strain shirota on azoxymethane-induced colonic aberrant crypt foci and colon cancer in the rat. |
| Lactobacillus casei Shirota |
Yakult |
The Effect of Lactobacillus casei Consumption in Improvement of Obsessive-Compulsive Disorder: an Animal Study. |
| Lactobacillus casei Shirota |
Yakult |
The effect of oral feeding of Lactobacillus casei strain Shirota on immunoglobulin E production in mice. |
| Lactobacillus casei Shirota |
Yakult |
The effects of heat-killed wild-type Lactobacillus casei Shirota on allergic immune responses in an allergy mouse model. |
| Lactobacillus casei Shirota |
Yakult |
The vaginal isolate Lactobacillus paracasei LPC-S01 (DSM 26760) is suitable for oral administration. |
| Lactobacillus casei W56 |
Ecologic® Barrier for Metabolic Health |
Dendritic Cell Targeting of Bovine Viral Diarrhea Virus E2 Protein Expressed by <i>Lactobacillus casei</i> Effectively Induces Antigen-Specific Immune Responses via Oral Vaccination. |
| Lactobacillus casei W56 |
Ecologic® Barrier for Metabolic Health |
Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant. |
| Lactobacillus crispatus LbV 88 (DSM 22566) |
AZO Complete Feminine Balance |
Effect of a yoghurt drink containing Lactobacillus strains on bacterial vaginosis in women - a double-blind, randomised, controlled clinical pilot trial. |
| Lactobacillus crispatus LbV 88 (DSM 22566) |
AZO Complete Feminine Balance |
Impact of oral administration of four <i>Lactobacillus</i> strains on Nugent score - systematic review and meta-analysis. |
| Lactobacillus fermentum ME-3 |
Reg'Activ Essential ME-3 |
[Antioxidant properties of lactic acid bacteria--probiotic and yogurt strains]. |
| Lactobacillus gasseri LbV 150N (DSM 22583) |
AZO Complete Feminine Balance |
Effect of a yoghurt drink containing Lactobacillus strains on bacterial vaginosis in women - a double-blind, randomised, controlled clinical pilot trial. |
| Lactobacillus gasseri LbV 150N (DSM 22583) |
AZO Complete Feminine Balance |
Impact of oral administration of four <i>Lactobacillus</i> strains on Nugent score - systematic review and meta-analysis. |
| Lactobacillus gasseri SBT2055 |
gasseri SP strain capsule |
Establishment of orally-administered Lactobacillus gasseri SBT2055SR in the gastrointestinal tract of humans and its influence on intestinal microflora and metabolism. |
| Lactobacillus gasseri SBT2055 |
gasseri SP strain capsule |
Oral administration of Lactobacillus gasseri SBT2055 is effective for preventing influenza in mice. |
| Lactobacillus gasseri SBT2055 |
gasseri SP strain capsule |
Oral administration of Lactobacillus gasseri SBT2055 is effective in preventing Porphyromonas gingivalis-accelerated periodontal disease. |
| LACTOBACILLUS HELVETICUS L10 |
LACTOBACILLUS HELVETICUS LAFTI® L10 |
DNA-based gels for oral delivery of probiotic bacteria. |
| LACTOBACILLUS HELVETICUS L10 |
LACTOBACILLUS HELVETICUS LAFTI® L10 |
Lactobacillus helveticus Lafti L10 Supplementation Modulates Mucosal and Humoral Immunity in Elite Athletes: A Randomized, Double-Blind, Placebo-Controlled Trial. |
| LACTOBACILLUS HELVETICUS L10 |
LACTOBACILLUS HELVETICUS LAFTI® L10 |
Multi-domain probiotic consortium as an alternative to chemical remediation of oil spills at coral reefs and adjacent sites. |
| LACTOBACILLUS HELVETICUS L10 |
LACTOBACILLUS HELVETICUS LAFTI® L10 |
Oral administration of the probiotic bacterium Lactobacillus acidophilus strain L-55 modulates the immunological parameters of the laying hen inoculated with a Newcastle disease virus-based live attenuated vaccine. |
| LACTOBACILLUS HELVETICUS L10 |
LACTOBACILLUS HELVETICUS LAFTI® L10 |
Oral nanozyme-engineered probiotics for the treatment of ulcerative colitis. |
| LACTOBACILLUS HELVETICUS L10 |
LACTOBACILLUS HELVETICUS LAFTI® L10 |
Oral therapeutic administration of a probiotic mixture suppresses established Th2 responses and systemic anaphylaxis in a murine model of food allergy. |
| LACTOBACILLUS HELVETICUS L10 |
LACTOBACILLUS HELVETICUS LAFTI® L10 |
Pharmacotherapy for inducing and maintaining remission in pouchitis. |
| LACTOBACILLUS HELVETICUS L10 |
LACTOBACILLUS HELVETICUS LAFTI® L10 |
The Bifidobacterium dentium Bd1 genome sequence reflects its genetic adaptation to the human oral cavity. |
| LACTOBACILLUS HELVETICUS L10 |
LACTOBACILLUS HELVETICUS LAFTI® L10 |
Vaginal and oral use of probiotics as adjunctive therapy to fluconazole in patients with vulvovaginal candidiasis: A clinical trial on Iranian women. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
A concerted probiotic activity to inhibit periodontitis-associated bacteria. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
A probiotic lozenge administered medical device and its effect on salivary mutans streptococci and lactobacilli. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Beneficial modulation of human health in the oral cavity and beyond using bacteriocin-like inhibitory substance-producing streptococcal probiotics. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Bifidobacterium longum R0175 attenuates post-myocardial infarction depressive-like behaviour in rats. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Calcium phosphate supplementation increases faecal Lactobacillus spp. in a randomised trial of young adults. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Combination of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 reduces post-myocardial infarction depression symptoms and restores intestinal permeability in a rat model. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Effect of chewing gums containing the probiotic bacterium Lactobacillus reuteri on oral malodour. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Effect of Lactobacillus reuteri on Cell Viability and PGE<sub>2</sub> Production in Human Gingival Fibroblasts. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Effect of Probiotic Bacteria on Oral Candida in Frail Elderly. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Effect of probiotics on digestibility and immunity in infants: A study protocol for a randomized controlled trial. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Effects of <i>Lactobacillus reuteri</i>-containing lozenges on healing after surgical removal of mandibular third molars: a randomised controlled trial. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Glycerol strengthens probiotic effect of Limosilactobacillus reuteri in oral biofilms: A synergistic synbiotic approach. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Growth inhibition of oral mutans streptococci and candida by commercial probiotic lactobacilli--an in vitro study. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Immunomodulatory impact of a synbiotic in T(h)1 and T(h)2 models of infection. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Influence of dietary supplementation with Lactobacillus reuteri on the oral flora of healthy subjects. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Influence of probiotics on the periodontium, the oral microbiota and the immune response during orthodontic treatment in adolescent and adult patients (ProMB Trial): study protocol for a prospective, double-blind, controlled, randomized clinical trial. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Ingestion of probiotic (Lactobacillus helveticus and Bifidobacterium longum) alters intestinal microbial structure and behavioral expression following social defeat stress. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 ameliorates chemotherapy-induced oral mucositis. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Lactobacillus reuteri supplements do not affect salivary IgA or cytokine levels in healthy subjects: A randomized, double-blind, placebo-controlled, cross-over trial. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Oral Colonisation after the Administration of Drops Containing Lactobacillus reuteri. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Oral Probiotics Ameliorate the Behavioral Deficits Induced by Chronic Mild Stress in Mice via the Gut Microbiota-Inflammation Axis. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Oral probiotics in the management of gingivitis in diabetic patients: a double blinded randomized controlled study. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Probiotic <i>Lactobacillus reuteri</i> has antifungal effects on oral <i>Candida</i> species <i>in vitro</i>. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Probiotic effects of orally administered Lactobacillus reuteri-containing tablets on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Probiotic Lactobacillus reuteri strains ATCC PTA 5289 and ATCC 55730 differ in their cariogenic properties in vitro. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Probiotic supplements (Lactobacillus reuteri DSM 17938 and ATCC PTA 5289) do not affect regrowth of mutans streptococci after full-mouth disinfection with chlorhexidine: a randomized controlled multicenter trial. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Randomized pilot study on probiotic effects on recurrent candidiasis in oral lichen planus patients. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Short-term effect of chewing gums containing probiotic Lactobacillus reuteri on the levels of inflammatory mediators in gingival crevicular fluid. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
Strain-Specific Probiotic Properties of Bifidobacteria and Lactobacilli for the Prevention of Diarrhea Caused by Rotavirus in a Preclinical Model. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
The Effects of Probiotic Formulation Pretreatment (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) on a Lipopolysaccharide Rat Model. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
The role of luminal factors in the recovery of gastric function and behavioral changes after chronic Helicobacter pylori infection. |
| Lactobacillus helveticus R0052 |
Calm Biotic® |
The use of Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 on oral health indexes in a school population: A pilot randomized clinical trial. |
| Lactobacillus jensenii LbV 116 (DSM 22567) |
AZO Complete Feminine Balance |
Effect of a yoghurt drink containing Lactobacillus strains on bacterial vaginosis in women - a double-blind, randomised, controlled clinical pilot trial. |
| Lactobacillus jensenii LbV 116 (DSM 22567) |
AZO Complete Feminine Balance |
Impact of oral administration of four <i>Lactobacillus</i> strains on Nugent score - systematic review and meta-analysis. |
| Lactobacillus Kefiri LKF01 (DSM 32079) LKEF |
Kefibios |
Ability of Lactobacillus kefiri LKF01 (DSM32079) to colonize the intestinal environment and modify the gut microbiota composition of healthy individuals. |
| Lactobacillus paracasei 8700:2 |
UltraFlora® Cold Support |
Effects of <i>Lactobacillus plantarum</i> and <i>Lactobacillus paracasei</i> on the Peripheral Immune Response in Children with Celiac Disease Autoimmunity: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. |
| Lactobacillus paracasei F-19 |
Optibac Probiotics For Women Probiotics |
[Effectiveness of oral administration of Lactobacillus paracasei subsp. paracasei F19 in association with vaginal suppositories of Lactobacillus acidofilus in the treatment of vaginosis and in the prevention of recurrent vaginitis]. |
| Lactobacillus paracasei Lpc-37 |
Custom Probiotics |
A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO). |
| Lactobacillus paracasei Lpc-37 |
Custom Probiotics |
EFFECT OF PROBIOTIC ORAL ADMINISTRATION ON SKIN WOUND HEALING IN RATS. |
| Lactobacillus paracasei Lpc-37 |
Custom Probiotics |
EFFECT OF SUPPLEMENTATION WITH PROBIOTICS ON COLONIC ANASTOMOSES IN RATS: MORPHOLOGICAL AND TENSIOMETRIC STUDY. |
| Lactobacillus paracasei Lpc-37 |
Custom Probiotics |
Metal-Phenolic Network Directed Coating of Single Probiotic Cell Followed by Photoinitiated Thiol-Ene Click Fortification to Enhance Oral Therapy. |
| Lactobacillus paracasei Lpc-37 |
Custom Probiotics |
Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection. |
| Lactobacillus paracasei Lpc-37 |
Custom Probiotics |
Safety evaluation of HOWARU<sup>®</sup> Restore (Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium animalis subsp. lactis Bl-04 and B. lactis Bi-07) for antibiotic resistance, genomic risk factors, and acute toxicity. |
| Lactobacillus paracasei Lpc-37 |
Custom Probiotics |
Strain specific stress-modulating effects of candidate probiotics: A systematic screening in a mouse model of chronic restraint stress. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
A prospective randomised study of the probiotic Lactobacillus plantarum 299V on indices of gut barrier function in elective surgical patients. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
A prospective randomised trial of probiotics in critically ill patients. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Adhesion of the probiotic bacterium Lactobacillus plantarum 299v onto the gut mucosa in critically ill patients: a randomised open trial. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
An investigation into the effect of a probiotic on gut immune function in surgical patients. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Bifidobacteria Encapsulation and Viability of Probiotic Culture during Oral Delivery in a Milk Drink Matrix. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Coaggregation between probiotic bacteria and caries-associated strains: an in vitro study. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Effects of Lactobacillus plantarum on the intestinal morphology, intestinal barrier function and microbiota composition of suckling piglets. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Efficacy of Lactiplantibacillus plantarum 299 and 299v against nosocomial oropharyngeal pathogens in vitro and as an oral prophylactic treatment in a randomized, controlled clinical trial. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Growth inhibition of oral mutans streptococci and candida by commercial probiotic lactobacilli--an in vitro study. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Improving in vivo conversion of oleuropein into hydroxytyrosol by oral granules containing probiotic Lactobacillus plantarum 299v and an Olea europaea standardized extract. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
In Vitro Evaluation of the Probiotic Potential of Halotolerant Lactobacilli Isolated from a Ripened Tropical Mexican Cheese. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Lactobacillus Plantarum 299v Changes miRNA Expression in the Intestines of Piglets and Leads to Downregulation of LITAF by Regulating ssc-miR-450a. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Lactobacillus plantarum 299v does not reduce enteric bacteria or bacterial translocation in patients undergoing colon resection. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Lactobacillus plantarum 299v Supplementation Improves Vascular Endothelial Function and Reduces Inflammatory Biomarkers in Men With Stable Coronary Artery Disease. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Microbial products from probiotic bacteria inhibit Salmonella enteritidis 857-induced IL-8 synthesis in Caco-2 cells. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Natural gum modified emulsion gel as single carrier for the oral delivery of probiotic-drug combination. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Oral Administration of <i>Lactobacillus plantarum</i> 299v Reduces Cortisol Levels in Human Saliva during Examination Induced Stress: A Randomized, Double-Blind Controlled Trial. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Oral administration of Lactobacillus plantarum 299v modulates gene expression in the ileum of pigs: prediction of crosstalk between intestinal immune cells and sub-mucosal adipocytes. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Oral and intestinal microflora in 5-fluorouracil treated rats, translocation to cervical and mesenteric lymph nodes and effects of probiotic bacteria. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Probiotics and immune response. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Probiotics versus antibiotic decontamination of the digestive tract: infection and mortality. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Pulse probiotic administration induces repeated small intestinal Muc3 expression in rats. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
Streptococcus strain D19(T) as a probiotic candidate to modulate oral health. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
The Effect of <i>Lactobacillus plantarum</i> 299v on Iron Status and Physical Performance in Female Iron-Deficient Athletes: A Randomized Controlled Trial. |
| Lactobacillus plantarum 299v |
Jarrow Formulas Ideal Bowel Support |
The Effect of Lactobacillus plantarum 299v on the Incidence of Clostridium difficile Infection in High Risk Patients Treated with Antibiotics. |
| Lactobacillus plantarum HEAL9 |
UltraFlora® Cold Support |
Effects of <i>Lactobacillus plantarum</i> and <i>Lactobacillus paracasei</i> on the Peripheral Immune Response in Children with Celiac Disease Autoimmunity: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. |
| Lactobacillus plantarum HEAL9 |
UltraFlora® Cold Support |
Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study. |
| Lactobacillus plantarum Lp-115 |
Custom Probiotics |
Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model. |
| lactobacillus plantarum LP45 |
Natealth |
[The Immunomodulatory and Anti-allergy Effects of Lactobacilli]. |
| lactobacillus plantarum LP45 |
Natealth |
Long-term combined administration of Bifidobacterium bifidum TMC3115 and Lactobacillus plantarum 45 alleviates spatial memory impairment and gut dysbiosis in APP/PS1 mice. |
| lactobacillus plantarum ps128 |
Neurobiotique PS128 |
Effect of Daily Oral <i>Lactobacillus plantarum</i> PS128 on Exercise Capacity Recovery after a Half-Marathon. |
| lactobacillus plantarum ps128 |
Neurobiotique PS128 |
Probiotic and Oxytocin Combination Therapy in Patients with Autism Spectrum Disorder: A Randomized, Double-Blinded, Placebo-Controlled Pilot Trial. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
A concerted probiotic activity to inhibit periodontitis-associated bacteria. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
A probiotic lozenge administered medical device and its effect on salivary mutans streptococci and lactobacilli. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Effect of chewing gums containing the probiotic bacterium Lactobacillus reuteri on oral malodour. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Effect of Lactobacillus reuteri on Cell Viability and PGE<sub>2</sub> Production in Human Gingival Fibroblasts. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Effect of Probiotic Bacteria on Oral Candida in Frail Elderly. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Effects of <i>Lactobacillus reuteri</i>-containing lozenges on healing after surgical removal of mandibular third molars: a randomised controlled trial. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Glycerol strengthens probiotic effect of Limosilactobacillus reuteri in oral biofilms: A synergistic synbiotic approach. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Growth inhibition of oral mutans streptococci and candida by commercial probiotic lactobacilli--an in vitro study. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Influence of dietary supplementation with Lactobacillus reuteri on the oral flora of healthy subjects. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Influence of probiotics on the periodontium, the oral microbiota and the immune response during orthodontic treatment in adolescent and adult patients (ProMB Trial): study protocol for a prospective, double-blind, controlled, randomized clinical trial. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 ameliorates chemotherapy-induced oral mucositis. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Lactobacillus reuteri supplements do not affect salivary IgA or cytokine levels in healthy subjects: A randomized, double-blind, placebo-controlled, cross-over trial. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Oral Colonisation after the Administration of Drops Containing Lactobacillus reuteri. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Oral probiotics in the management of gingivitis in diabetic patients: a double blinded randomized controlled study. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Probiotic <i>Lactobacillus reuteri</i> has antifungal effects on oral <i>Candida</i> species <i>in vitro</i>. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Probiotic effects of orally administered Lactobacillus reuteri-containing tablets on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Probiotic Lactobacillus reuteri strains ATCC PTA 5289 and ATCC 55730 differ in their cariogenic properties in vitro. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Probiotic supplements (Lactobacillus reuteri DSM 17938 and ATCC PTA 5289) do not affect regrowth of mutans streptococci after full-mouth disinfection with chlorhexidine: a randomized controlled multicenter trial. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Randomized pilot study on probiotic effects on recurrent candidiasis in oral lichen planus patients. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
Short-term effect of chewing gums containing probiotic Lactobacillus reuteri on the levels of inflammatory mediators in gingival crevicular fluid. |
| Lactobacillus reuteri ATCC PTA 5289 |
BioGaia® ProDentis |
The use of Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 on oral health indexes in a school population: A pilot randomized clinical trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
<i>Lactobacillus reuteri</i> DSM 17938 feeding of healthy newborn mice regulates immune responses while modulating gut microbiota and boosting beneficial metabolites. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
A concerted probiotic activity to inhibit periodontitis-associated bacteria. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Characterization of biosurfactants produced by Lactobacillus spp. and their activity against oral streptococci biofilm. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Consumption of Lactobacillus reuteri-containing lozenges improves periodontal health in navy sailors at sea: A randomized controlled trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Crying Time and ROR?/FOXP3 Expression in Lactobacillus reuteri DSM17938-Treated Infants with Colic: A Randomized Trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Cytokine Secretion, Viability, and Real-Time Proliferation of Apical-Papilla Stem Cells Upon Exposure to Oral Bacteria. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT/mTOR/LC-3II pathways. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Effect of chewing gums containing the probiotic bacterium Lactobacillus reuteri on oral malodour. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Effect of Lactobacillus reuteri on Cell Viability and PGE<sub>2</sub> Production in Human Gingival Fibroblasts. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Effect of Probiotic Bacteria on Oral Candida in Frail Elderly. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Effects of <i>Lactobacillus reuteri</i>-containing lozenges on healing after surgical removal of mandibular third molars: a randomised controlled trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Efficacy of an Oral Rehydration Solution Enriched with <i>Lactobacillus reuteri DSM 17938</i> and Zinc in the Management of Acute Diarrhoea in Infants: A Randomized, Double-Blind, Placebo-Controlled Trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Efficacy of Lactobacillus Reuteri DSM 17938 for the Treatment of Acute Gastroenteritis in Children: Protocol of a Randomized Controlled Trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Influence of probiotics on the periodontium, the oral microbiota and the immune response during orthodontic treatment in adolescent and adult patients (ProMB Trial): study protocol for a prospective, double-blind, controlled, randomized clinical trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Lack of an effect of Lactobacillus reuteri DSM 17938 in preventing nosocomial diarrhea in children: a randomized, double-blind, placebo-controlled trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 ameliorates chemotherapy-induced oral mucositis. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Lactobacillus reuteri DSM 17938 in the prevention of antibiotic-associated diarrhoea in children: protocol of a randomised controlled trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Lactobacillus reuteri effects on maternal separation stress in newborn mice. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Lactobacillus Reuteri for the prevention of necrotising enterocolitis in very low birthweight infants: a randomised controlled trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Lactobacillus reuteri prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in Apoe-/- mice. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Lactobacillus reuteri supplements do not affect salivary IgA or cytokine levels in healthy subjects: A randomized, double-blind, placebo-controlled, cross-over trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: A randomized controlled trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Microvesicles from Lactobacillus reuteri (DSM-17938) completely reproduce modulation of gut motility by bacteria in mice. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Mind the gut: probiotics in paediatric neurogastroenterology. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Oral Colonisation after the Administration of Drops Containing Lactobacillus reuteri. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Oral Microbiota Shift after 12-Week Supplementation with Lactobacillus reuteri DSM 17938 and PTA 5289; A Randomized Control Trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Oral probiotics in the management of gingivitis in diabetic patients: a double blinded randomized controlled study. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Preventive effects of oral probiotic on infantile colic: a prospective, randomised, blinded, controlled trial using Lactobacillus reuteri DSM 17938. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Probiotic <i>Lactobacillus reuteri</i> has antifungal effects on oral <i>Candida</i> species <i>in vitro</i>. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Probiotic effects of orally administered Lactobacillus reuteri-containing tablets on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Probiotic supplements (Lactobacillus reuteri DSM 17938 and ATCC PTA 5289) do not affect regrowth of mutans streptococci after full-mouth disinfection with chlorhexidine: a randomized controlled multicenter trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Probiotics for Irritable Bowel Syndrome: Clinical Data in Children. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Probiotics for the Management of Infantile Colic: A Systematic Review. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Probiotics promoted head growth in extremely low birthweight infants in a double-blind placebo-controlled trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Probiotics stimulate enterocyte migration and microbial diversity in the neonatal mouse intestine. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Probiotics to improve outcomes of colic in the community: protocol for the Baby Biotics randomised controlled trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Protective effect of Lactobacillus reuteri DSM 17938 against experimental necrotizing enterocolitis is mediated by Toll-like receptor 2. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Randomized pilot study on probiotic effects on recurrent candidiasis in oral lichen planus patients. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Rapid enteric testing to permit targeted antimicrobial therapy, with and without Lactobacillus reuteri probiotics, for paediatric acute diarrhoeal disease in Botswana: A pilot, randomized, factorial, controlled trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Regulatory T cells and Toll-like receptor 2 and 4 mRNA expression in infants with colic treated with <i>Lactobacillus reuteri</i> DSM17938. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Spatiotemporal maps reveal regional differences in the effects on gut motility for Lactobacillus reuteri and rhamnosus strains. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
The early administration of Lactobacillus reuteri DSM 17938 controls regurgitation episodes in full-term breastfed infants. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic Lactobacillus reuteri DSM 17938. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
The use of Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 on oral health indexes in a school population: A pilot randomized clinical trial. |
| Lactobacillus reuteri DSM 17938 |
BioGaia® |
Urinary metabolome of infants with colic treated with Lactobacillus reuteri DSM 17938: a pilot randomized trial. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
[A study of non-antibiotic versus antibiotic prophylaxis for recurrent urinary-tract infections in women (the NAPRUTI study)]. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
[Effect of oral <i>Lactobacillus</i> <i>rhamnosus</i> GR-1 and <i>Lactobacillus</i> <i>reuteri</i> RC-14 on vaginal Group B <i>Streptococcus</i> colonization and vaginal microbiome in late pregnancy]. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
[Efficacy of Lactobacillus Rhamnosus GR-1 and of Lactobacillus Reuteri RC-14 in the treatment and prevention of vaginoses and bacterial vaginitis relapses]. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
A Randomized Controlled Open Label Crossover Trial to Study Vaginal Colonization of Orally Administered Lactobacillus Reuteri RC-14 and Rhamnosus GR-1 in Pregnant Women at High Risk for Preterm Labor. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Changes in vaginal microbiota following antimicrobial and probiotic therapy. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Effect of 25 weeks probiotic supplementation on immune function of HIV patients. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Effect of Oral Probiotic <i>Lactobacillus rhamnosus</i> GR-1 and <i>Lactobacillus</i> <i>reuteri</i> RC-14 on the Vaginal Microbiota, Cytokines and Chemokines in Pregnant Women. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Effect of probiotics on vaginal health in pregnancy. EFFPRO, a randomized controlled trial. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Effectiveness of oral intake of <i>Lactobacillus rhamnosus GR-1</i> and <i>Lactobacillus reuteri RC-14</i> on Group B <i>Streptococcus</i> colonization during pregnancy: a midwifery-led double-blind randomized controlled pilot trial. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 to prevent or cure bacterial vaginosis among women with HIV. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Non-Antibiotic Prophylaxis for Urinary Tract Infections. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 to reduce Group B Streptococcus colonization in pregnant women: A randomized controlled trial. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Oral probiotics and the female urinary microbiome: a double-blinded randomized placebo-controlled trial. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Pilot assessment of probiotics for pregnant women in Rwanda. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Prebiotic, Probiotic, and Synbiotic Consumption Alter Behavioral Variables and Intestinal Permeability and Microbiota in BTBR Mice. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trial. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
The influence of probiotics on genital high-risk human papilloma virus clearance and quality of cervical smear: a randomized placebo-controlled trial. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
The influence of probiotics on the cervical malignancy diagnostics quality. |
| Lactobacillus reuteri RC-14 |
RepHresh™ Pro-B™ Probiotic |
Vaginal & gut microbiota diversity in pregnant women with bacterial vaginosis & effect of oral probiotics: An exploratory study. |
| Lactobacillus rhamnosus CLR2 |
Bio-K+ |
Investigating the therapeutic potential of a probiotic in a clinical population with chronic hand dermatitis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
[Cholic acid metabolism in human fecal cultures during diet supplementation with Lacto-bacillus rhamnosus GG]. |
| Lactobacillus rhamnosus GG |
Culturelle® |
[Prophylactic effect of Lactobacillus GG in animal colitis and its effect on cytokine secretion and mucin gene expressions]. |
| Lactobacillus rhamnosus GG |
Culturelle® |
[The Immunomodulatory and Anti-allergy Effects of Lactobacilli]. |
| Lactobacillus rhamnosus GG |
Culturelle® |
<i>Lactobacillus reuteri</i> ZJ617 maintains intestinal integrity via regulating tight junction, autophagy and apoptosis in mice challenged with lipopolysaccharide. |
| Lactobacillus rhamnosus GG |
Culturelle® |
<i>Lactobacillus rhamnosus</i> GG attenuates tenofovir disoproxil fumarate-induced bone loss in male mice <i>via</i> gut-microbiota-dependent anti-inflammation. |
| Lactobacillus rhamnosus GG |
Culturelle® |
<i>Lactobacillus rhamnosus</i> GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade. |
| Lactobacillus rhamnosus GG |
Culturelle® |
<i>Lactobacillus rhamnosus</i> GG Reduces <i>ß-conglycinin-</i>Allergy-Induced Apoptotic Cells by Regulating <i>Bacteroides</i> and Bile Secretion Pathway in Intestinal Contents of BALB/c Mice. |
| Lactobacillus rhamnosus GG |
Culturelle® |
<i>Lactobacillus rhamnosus</i> GG reverses mortality of neonatal mice against <i>Salmonella</i> challenge. |
| Lactobacillus rhamnosus GG |
Culturelle® |
<i>Lactobacillus</i> raises <i>in vitro</i> anticancer effect of geniposide in HSC-3 human oral squamous cell carcinoma cells. |
| Lactobacillus rhamnosus GG |
Culturelle® |
A novel consortium of Lactobacillus rhamnosus and Streptococcus thermophilus for increased access to functional fermented foods. |
| Lactobacillus rhamnosus GG |
Culturelle® |
A Novel Postbiotic From <i>Lactobacillus rhamnosus</i> GG With a Beneficial Effect on Intestinal Barrier Function. |
| Lactobacillus rhamnosus GG |
Culturelle® |
A randomised controlled demonstration trial of multifaceted nutritional intervention and or probiotics: the healthy mums and babies (HUMBA) trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
A randomized clinical trial examining the impact of LGG probiotic supplementation on psychological status in middle-aged and older adults. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Adhesion, anti-adhesion and aggregation properties relating to surface charges of selected Lactobacillus strains: study in Caco-2 and H357 cells. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Administration of Extensive Hydrolysates From Caseins and <i>Lactobacillus rhamnosus</i> GG Probiotic Does Not Prevent Cow`s Milk Proteins Allergy in a Mouse Model. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Administration of oral probiotic bacteria to pregnant women causes temporary infantile colonization. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Administration of probiotics Lactobacillus rhamnosus GG and Lactobacillus gasseri K7 during pregnancy and lactation changes mouse mesenteric lymph nodes and mammary gland microbiota. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Amelioration of ovalbumin induced allergic symptoms in Balb/c mice by potentially probiotic strains of lactobacilli. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Anti-allergic effects of Lactobacillus crispatus KT-11 strain on ovalbumin-sensitized BALB/c mice. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Antifungal defense of probiotic Lactobacillus rhamnosus GG is mediated by blocking adhesion and nutrient depletion. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Anti-inflammatory capacity of Lactobacillus rhamnosus GG in monophasic variant Salmonella infected piglets is correlated with impeding NLRP6-mediated host inflammatory responses. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Biopolymer-Based Minimal Formulations Boost Viability and Metabolic Functionality of Probiotics Lactobacillus rhamnosus GG through Gastrointestinal Passage. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Bugs for atopy: the Lactobacillus rhamnosus GG strategy for food allergy prevention and treatment in children. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Chemopreventive effect of Lactobacillus rhamnosus on growth of a subcutaneously implanted bladder cancer cell line in the mouse. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Coaggregation between probiotic bacteria and caries-associated strains: an in vitro study. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Colonization of Lactobacillus rhamnosus GG in the oral cavity. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Comparative genome analysis of Lactobacillus rhamnosus clinical isolates from initial stages of dental pulp infection: identification of a new exopolysaccharide cluster. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Comparative genomic and functional analysis of 100 Lactobacillus rhamnosus strains and their comparison with strain GG. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Complexity of vaginal microflora as analyzed by PCR denaturing gradient gel electrophoresis in a patient with recurrent bacterial vaginosis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Core-shell alginate@silica microparticles encapsulating probiotics. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Crude Turmeric Extract Improves the Suppressive Effects of <i>Lactobacillus rhamnosus</i> GG on Allergic Inflammation in a Murine Model of House Dust Mite-Induced Asthma. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Decolonization of gastrointestinal carriage of vancomycin-resistant Enterococcus faecium: case series and review of literature. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Delayed gut microbiota development in high-risk for asthma infants is temporarily modifiable by Lactobacillus supplementation. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Development of enteric polymer-based microspheres by spray-drying for colonic delivery of Lactobacillus rhamnosus GG. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Dietary addition of Lactobacillus rhamnosus GG impairs the health of Escherichia coli F4-challenged piglets. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Dietary Lactobacillus rhamnosus GG Supplementation Improves the Mucosal Barrier Function in the Intestine of Weaned Piglets Challenged by Porcine Rotavirus. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Dietary sugar utilisation by putative oral probiotics. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Divergent immunomodulating effects of probiotics on T cell responses to oral attenuated human rotavirus vaccine and virulent human rotavirus infection in a neonatal gnotobiotic piglet disease model. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Doses Lactobacillus reuteri depend on adhesive ability to modulate the intestinal immune response and metabolism in mice challenged with lipopolysaccharide. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effect of 3 lactobacilli on immunoregulation and intestinal microbiota in a ß-lactoglobulin-induced allergic mouse model. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effect of Lactobacillus rhamnosus and Bifidobacterium lactis on gingival health, dental plaque, and periodontopathogens in adolescents: a randomised placebo-controlled clinical trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effect of Lactobacillus rhamnosus GG immunopathologic changes in chronic mouse asthma model. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effect of Lactobacillus rhamnosus GG in persistent diarrhea in Indian children: a randomized controlled trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effect of Lactobacillus rhamnosus GG on rBet v1 and rMal d1 specific IgA in the saliva of patients with birch pollen allergy. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effect of Lactobacillus rhamnosus strain GG (ATCC 53103) on the growth of Streptococcus sobrinus in vitro. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effect of Probiotic Administration on Serum Tryptophan Metabolites in Pediatric Type 1 Diabetes Patients. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effect of probiotic supplementation on cognitive function in children and adolescents: a systematic review of randomised trials. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effect of Probiotic Use on Antibiotic Administration Among Care Home Residents: A Randomized Clinical Trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effect of probiotics and breastfeeding on the bifidobacterium and lactobacillus/enterococcus microbiota and humoral immune responses. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effects of <i>Lactobacillus rhamnosus</i> GG and <i>Bifidobacterium lactis</i> Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: protocol of a randomised controlled trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effects of a nine-strain bacterial synbiotic compared to simethicone in colicky babies - an open-label randomised study. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effects of immunomodulatory supplementation with Lactobacillus rhamnosus on airway inflammation in a mouse asthma model. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effects of Lactobacillus rhamnosus GG and Lactobacillus reuteri R2LC on acetic acid-induced colitis in rats. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effects of Lactobacillus rhamnosus GG as a probiotic on neonatal hyperbilirubinemia. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effects of Lactobacillus rhamnosus GG on saliva-derived microcosms. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effects of Lactobacillus rhamnosus GG on the maturation and differentiation of dendritic cells in rotavirus-infected mice. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effects of Lactobacillus rhamnosus GG supplementation on cow`s milk allergy in a mouse model. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effects of orally administered viable Lactobacillus rhamnosus GG and Propionibacterium freudenreichii subsp. shermanii JS on mouse lymphocyte proliferation. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effects of probiotic administration on immune responses of children and adolescents with type 1 diabetes to a quadrivalent inactivated influenza vaccine. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Effects of the viability of Lactobacillus rhamnosus GG on rotavirus infection in neonatal rats. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Efficacy of Lactobacillus Reuteri DSM 17938 for the Treatment of Acute Gastroenteritis in Children: Protocol of a Randomized Controlled Trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Efficacy of probiotic Lactobacillus GG on allergic sensitization and asthma in infants at risk. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Elastic recovery of filler-binders to safeguard viability of Lactobacillus rhamnosus GG during direct compression. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Epigenetic features of FoxP3 in children with cow`s milk allergy. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Escherichia coli Nissle 1917 Enhances Efficacy of Oral Attenuated Human Rotavirus Vaccine in a Gnotobiotic Piglet Model. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Evaluation of indigenous lactic acid bacteria of raw mare milk from pastoral areas in Xinjiang, China, for potential use in probiotic fermented dairy products. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Exosomes isolated from sera of mice fed Lactobacillus strains affect inflammatory cytokine production in macrophages in vitro. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Extensively hydrolyzed casein formula alone or with L. rhamnosus GG reduces ß-lactoglobulin sensitization in mice. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow`s milk allergy: 3-year randomized controlled trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Factors Associated With Nonadherence in an Emergency Department-based Multicenter Randomized Clinical Trial of a Probiotic in Children With Acute Gastroenteritis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Fecal Changes Following Introduction of Milk in Infants With Outgrowing Non-IgE Cow`s Milk Protein Allergy Are Influenced by Previous Consumption of the Probiotic LGG. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Fermented milk with Lactobacillus curvatus SMFM2016-NK alleviates periodontal and gut inflammation, and alters oral and gut microbiota. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Formula selection for management of children with cow`s milk allergy influences the rate of acquisition of tolerance: a prospective multicenter study. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Growth phase-associated changes in the proteome and transcriptome of Lactobacillus rhamnosus GG in industrial-type whey medium. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Gut Bifidobacteria enrichment following oral Lactobacillus-supplementation is associated with clinical improvements in children with cystic fibrosis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
High protective efficacy of rice bran against human rotavirus diarrhea via enhancing probiotic growth, gut barrier function, and innate immunity. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Human rhinovirus in experimental infection after peroral Lactobacillus rhamnosus GG consumption, a pilot study. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Immunomodulatory Potential of Weissella cibaria in Aged C57BL/6J Mice. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Immunomodulatory properties of Enterococcus faecium JWS 833 isolated from duck intestinal tract and suppression of Listeria monocytogenes infection. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Impact of a novel synbiotic supplementation during gestation and lactation on immune responses in the Swiss albino mice offspring. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Impact of orally administered lozenges with Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12 on the number of salivary mutans streptococci, amount of plaque, gingival inflammation and the oral microbiome in healthy adults. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Impact of Potential Probiotic Lactobacillus Strains on Host Growth and Development in a Drosophila melanogaster Model. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Importance of pressure plasticity during compression of probiotic tablet formulations. |
| Lactobacillus rhamnosus GG |
Culturelle® |
In vitro anti-inflammatory and antibiofilm activities of bacterial lysates from lactobacilli against oral pathogenic bacteria. |
| Lactobacillus rhamnosus GG |
Culturelle® |
In vitro evaluation of yoghurt starter lactobacilli and Lactobacillus rhamnosus GG adhesion to saliva-coated surfaces. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Inactivation of Lactobacillus rhamnosus GG by fixation modifies its probiotic properties. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Infant behavioral state and stool microbiome in infants receiving Lactocaseibacillus rhamnosus GG in formula: randomized controlled trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Infant food allergy: where are we now? |
| Lactobacillus rhamnosus GG |
Culturelle® |
Influence of orally administered Lactobacillus GG on respiratory immune response in a murine model of diet-induced obesity. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Influence of Probiotics on the Salivary Microflora Oral Streptococci and Their Integration into Oral Biofilm. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Ingestion of heat-treated Lactobacillus rhamnosus GG prevents development of atopic dermatitis in NC/Nga mice. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Inhibition of enteropathogens adhesion to human enterocyte-like HT-29 cells by a dairy strain of Propionibacterium acidipropionici. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Inhibitory activity in vitro of probiotic lactobacilli against oral Candida under different fermentation conditions. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Inhibitory effect of Lactobacillus salivarius on Streptococcus mutans biofilm formation. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Innate gut microbiota predisposes to high alcohol consumption. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Interaction of orally administered Lactobacillus rhamnosus GG with skin and gut microbiota and humoral immunity in infants with atopic dermatitis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Interactions between Lactobacillus rhamnosus GG and oral micro-organisms in an in vitro biofilm model. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Interplay between Lactobacillus rhamnosus GG and Candida and the involvement of exopolysaccharides. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Investigation of the Efficacy of Lactobacillus rhamnosus GG in Infants With Cow`s Milk Protein Allergy: a Randomised Double-Blind Placebo-Controlled Trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lack of effect of <i>Lactobacillus rhamnosus</i> GG and <i>Bifidobacterium lactis</i> Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: a randomised controlled trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacilli and Bifidobacteria enhance mucosal B cell responses and differentially modulate systemic antibody responses to an oral human rotavirus vaccine in a neonatal gnotobiotic pig disease model. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacilli for prevention of urogenital infections: a review. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus GG does not affect D-lactic acidosis in diarrheic calves, in a clinical setting. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus reuteri ZJ617 Culture Supernatant Attenuates Acute Liver Injury Induced in Mice by Lipopolysaccharide. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus CCFM1107 treatment ameliorates alcohol-induced liver injury in a mouse model of chronic alcohol feeding. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG and Bifidobacterium animalis MB5 induce intestinal but not systemic antigen-specific hyporesponsiveness in ovalbumin-immunized rats. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG and Bifidobacterium longum attenuate lung injury and inflammatory response in experimental sepsis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG antagonizes Giardia intestinalis induced oxidative stress and intestinal disaccharidases: an experimental study. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG Attenuates Lipopolysaccharide-Induced Inflammation and Barrier Dysfunction by Regulating MAPK/NF-?B Signaling and Modulating Metabolome in the Piglet Intestine. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG Dosage Affects the Adjuvanticity and Protection Against Rotavirus Diarrhea in Gnotobiotic Pigs. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG Effect on Behavior of Zebrafish During Chronic Ethanol Exposure. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG improves glucose tolerance through alleviating ER stress and suppressing macrophage activation in db/db mice. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG improves insulin sensitivity and reduces adiposity in high-fat diet-fed mice through enhancement of adiponectin production. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG in adenoid tissue: Double-blind, placebo-controlled, randomized clinical trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG in Experimental Oral Biofilms Exposed to Different Carbohydrate Sources. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG in the middle ear after randomized, double-blind, placebo-controlled oral administration. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG increases cyclooxygenase-2 expression and prostaglandin E2 secretion in colonic myofibroblasts via a MyD88-dependent mechanism during homeostasis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG induced protective effect on allergic airway inflammation is associated with gut microbiota. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG induces tumor regression in mice bearing orthotopic bladder tumors. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG modulates gastrointestinal absorption, excretion patterns, and toxicity in Holstein calves fed a single dose of aflatoxin B<sub>1</sub>. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG modulates innate signaling pathway and cytokine responses to rotavirus vaccine in intestinal mononuclear cells of gnotobiotic pigs transplanted with human gut microbiota. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG secreting an antigen and Interleukin-2 translocates across the gastrointestinal tract and induces an antigen specific immune response. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG supernatant enhance neonatal resistance to systemic Escherichia coli K1 infection by accelerating development of intestinal defense. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG supplementation during critical windows of gestation influences immune phenotype in Swiss albino mice offspring. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG treatment improves intestinal permeability and modulates microbiota dysbiosis in an experimental model of sepsis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus GG treatment potentiates ethanol-induced behavioral changes through modulation of intestinal epithelium in Danio rerio. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus induced epithelial cell apoptosis, ameliorates inflammation and prevents colon cancer development in an animal model. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus LRB mediated inhibition of oral streptococci. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus NCDC17 ameliorates type-2 diabetes by improving gut function, oxidative stress and inflammation in high-fat-diet fed and streptozotocintreated rats. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus sepsis associated with probiotic therapy in an extremely preterm infant: Pathogenesis and a review for clinicians. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactobacillus rhamnosus strain GG is a potential probiotic for calves. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lactococcus lactis Subspecies cremoris Elicits Protection Against Metabolic Changes Induced by a Western-Style Diet. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Limosilactobacillus reuteri inhibits the acid tolerance response in oral bacteria. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Lipoteichoic acid from Lactobacillus rhamnosus GG as an oral photoprotective agent against UV-induced carcinogenesis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Long-term safety assessment in children who received hydrolyzed protein formulas with Lactobacillus rhamnosus GG: a 5-year follow-up. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Management strategies in the treatment of neonatal and pediatric gastroenteritis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Microencapsulation of Lacticaseibacillus rhamnosus GG for Oral Delivery of Bovine Lactoferrin: Study of Encapsulation Stability, Cell Viability, and Drug Release. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Mitigation of the Toxic Effects of Periodontal Pathogens by Candidate Probiotics in Oral Keratinocytes, and in an Invertebrate Model. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Modulation of intestinal morphology and immunity in nile tilapia (Oreochromis niloticus) by Lactobacillus rhamnosus GG. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Mouthwash Effects on LGG-Integrated Experimental Oral Biofilms. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Neonatal supplementation of processed supernatant from Lactobacillus rhamnosus GG improves allergic airway inflammation in mice later in life. |
| Lactobacillus rhamnosus GG |
Culturelle® |
No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
No evidence of harms of probiotic Lactobacillus rhamnosus GG ATCC 53103 in healthy elderly-a phase I open label study to assess safety, tolerability and cytokine responses. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Nonpharmacologic treatment of functional abdominal pain disorders: a systematic review. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Obsessive-compulsive-like behaviors in house mice are attenuated by a probiotic (Lactobacillus rhamnosus GG). |
| Lactobacillus rhamnosus GG |
Culturelle® |
Oral Administration of <i>Lactobacillus rhamnosus</i> GG Ameliorates <i>Salmonella</i> Infantis-Induced Inflammation in a Pig Model via Activation of the IL-22BP/IL-22/STAT3 Pathway. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Oral administration of lactobacilli from human intestinal tract protects mice against influenza virus infection. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Oral administration of Lactobacillus rhamnosus GG to newborn piglets augments gut barrier function in pre-weaning piglets. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Oral administration of lipoteichoic acid from Lactobacillus rhamnosus GG overcomes UVB-induced immunosuppression and impairs skin tumor growth in mice. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Oral intake of Kluyveromyces marxianus B0399 plus Lactobacillus rhamnosus CECT 30579 to mitigate symptoms in COVID-19 patients: A randomized open label clinical trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Oral priming with oligodeoxynucleotide particles from Lactobacillus rhamnosus GG attenuates symptoms of dextran sodium sulfate-induced acute colitis in mice. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt, or cheese. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Preliminary evaluation of Lactobacillus rhamnosus strain GG, a potential probiotic in dogs. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Preliminary investigation of the probiotic potential of Lactobacillus rhamnosus strain GG in horses: fecal recovery following oral administration and safety. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Preserving viability of Lactobacillus rhamnosus GG in vitro and in vivo by a new encapsulation system. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic <i>Lactobacillus rhamnosus</i> GG Induces Alterations in Ileal Microbiota With Associated CD3<sup>-</sup>CD19<sup>-</sup>T-bet<sup>+</sup>IFN?<sup>+/-</sup> Cell Subset Homeostasis in Pigs Challenged With <i>Salmonella enterica</i> Serovar 4,[5],12:i:. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic administration reduces mortality and improves intestinal epithelial homeostasis in experimental sepsis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic attributes, antioxidant, anti-inflammatory and neuromodulatory effects of Enterococcus faecium CFR 3003: in vitro and in vivo evidence. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic effects on 5-fluorouracil-induced mucositis assessed by the sucrose breath test in rats. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic effects on experimental graft-versus-host disease: let them eat yogurt. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic intervention influences the salivary levels of Matrix Metalloproteinase (MMP)-9 and Tissue Inhibitor of metalloproteinases (TIMP)-1 in healthy adults. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic Lactobacillus fermentum KU200060 isolated from watery kimchi and its application in probiotic yogurt for oral health. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic Lactobacillus reuteri Prevents Postantibiotic Bone Loss by Reducing Intestinal Dysbiosis and Preventing Barrier Disruption. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic Lactobacillus rhamnosus GG (LGG) restores intestinal dysbacteriosis to alleviate upregulated inflammatory cytokines triggered by femoral diaphyseal fracture in adolescent rodent model. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic Lactobacillus rhamnosus GG and Aloe vera gel improve lipid profiles in hypercholesterolemic rats. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic Lactobacillus rhamnosus GG modulates the mucosal immune response in Giardia intestinalis-infected BALB/c mice. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic Lactobacillus rhamnosus GG prevents alveolar bone loss in a mouse model of experimental periodontitis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic Lactobacillus Rhamnosus GG Protects Against P. Gingivalis And F. Nucleatum Gut Dysbiosis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic Lactobacillus rhamnosus GG therapy and microbiological programming in infantile colic: a randomized, controlled trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic pre-administration reduces mortality in a mouse model of cecal ligation and puncture-induced sepsis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotic-induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory-dependent mechanisms in a murine model of asthma. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotics ameliorate chronic low-grade inflammation and fat accumulation with gut microbiota composition change in diet-induced obese mice models. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotics and colostrum/milk differentially affect neonatal humoral immune responses to oral rotavirus vaccine. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotics and gastrointestinal health. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotics and virulent human rotavirus modulate the transplanted human gut microbiota in gnotobiotic pigs. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients-A Systematic Review and Meta-Analysis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotics Lactobacillus rhamnosus GG, Lactobacillus acidophilus suppresses DMH-induced procarcinogenic fecal enzymes and preneoplastic aberrant crypt foci in early colon carcinogenesis in Sprague Dawley rats. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotics protect against RSV infection by modulating the microbiota-alveolar-macrophage axis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Probiotics protect against tenofovir-induced mandibular bone loss in mice by rescuing mandible-derived mesenchymal stem cell proliferation and osteogenic differentiation. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Proline-Rich Acidic Protein 1 (PRAP1) Protects the Gastrointestinal Epithelium From Irradiation-Induced Apoptosis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Prophylactic effects of oral administration of <i>Lactobacillus casei</i> on house dust mite-induced asthma in mice. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Protective Effect of <i>Lactobacillus rhamnosus</i> GG on TiO<sub>2</sub> Nanoparticles-Induced Oxidative Stress Damage in the Liver of Young Rats. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Protective Effect of Lactobacillus rhamnosus GG and its Supernatant against Myocardial Dysfunction in Obese Mice Exposed to Intermittent Hypoxia is Associated with the Activation of Nrf2 Pathway. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Protective effects of a novel Lactobacillus rhamnosus strain with probiotic characteristics against lipopolysaccharide-induced intestinal inflammation in vitro and in vivo. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Protective effects of Lactobacillus rhamnosus GG against dyslipidemia in high-fat diet-induced obese mice. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Protocol for a double-blind placebo-controlled trial to evaluate the efficacy of probiotics in reducing antibiotics for infection in care home residents: the Probiotics to Reduce Infections iN CarE home reSidentS (PRINCESS) trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Randomised, double-blind, placebo-controlled trial of Probiotics To Eliminate COVID-19 Transmission in Exposed Household Contacts (PROTECT-EHC): a clinical trial protocol. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Recovery of probiotic Lactobacillus rhamnosus GG in tonsil tissue after oral administration: randomised, placebo-controlled, double-blind clinical trial. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Restraining the TiO<sub>2</sub> nanoparticles-induced intestinal inflammation mediated by gut microbiota in juvenile rats via ingestion of Lactobacillus rhamnosus GG. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Routine Lactobacillus rhamnosus GG administration in VLBW infants: a retrospective, 6-year cohort study. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Severe oral infection due to Lactobacillus rhamnosus during induction chemotherapy for acute myeloid leukemia. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Shear-Enhanced Dynamic Adhesion of Lactobacillus rhamnosus GG on Intestinal Epithelia: Correlative Effect of Protein Expression and Interface Mechanics. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Short-term consumption of probiotic-containing cheese and its effect on dental caries risk factors. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Stability and activity of specific antibodies against Streptococcus mutans and Streptococcus sobrinus in bovine milk fermented with Lactobacillus rhamnosus strain GG or treated at ultra-high temperature. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Strain-specific differences in behaviour among Lacticaseibacillus rhamnosus cell wall mutants during direct compression. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Streptococcus strain D19(T) as a probiotic candidate to modulate oral health. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Symbiotic maple saps minimize disruption of the mice intestinal microbiota after oral antibiotic administration. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Taxonomic and strain-specific identification of the probiotic strain Lactobacillus rhamnosus 35 within the Lactobacillus casei group. |
| Lactobacillus rhamnosus GG |
Culturelle® |
The distinct effects of orally administered Lactobacillus rhamnosus GG and Lactococcus lactis subsp. lactis C59 on gene expression in the murine small intestine. |
| Lactobacillus rhamnosus GG |
Culturelle® |
The effect of probiotics and zinc supplementation on the immune response to oral rotavirus vaccine: A randomized, factorial design, placebo-controlled study among Indian infants. |
| Lactobacillus rhamnosus GG |
Culturelle® |
The Effects of Plasmacytoid Dendritic Cell-Stimulative Lactic Acid Bacteria, <i>Lactococcus lactis</i> Strain Plasma, on Exercise-Induced Fatigue and Recovery via Immunomodulatory Action. |
| Lactobacillus rhamnosus GG |
Culturelle® |
The probiotic Lactobacillus GG may augment intestinal host defense by regulating apoptosis and promoting cytoprotective responses in the developing murine gut. |
| Lactobacillus rhamnosus GG |
Culturelle® |
The Role of Biotics as a Therapeutic Strategy for Oral Mucositis - A Systematic Review. |
| Lactobacillus rhamnosus GG |
Culturelle® |
The role of probiotics in prevention of oral diseases. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Transcriptomic Profile of Whole Blood Cells from Elderly Subjects Fed Probiotic Bacteria Lactobacillus rhamnosus GG ATCC 53103 (LGG) in a Phase I Open Label Study. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Using Food and Nutritional Strategies to Induce Tolerance in Food-Allergic Children. |
| Lactobacillus rhamnosus GG |
Culturelle® |
Vaginal colonization by orally administered Lactobacillus rhamnosus GG. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
[A study of non-antibiotic versus antibiotic prophylaxis for recurrent urinary-tract infections in women (the NAPRUTI study)]. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
[Antifungal effect in selected natural compounds and probiotics and their possible use in prophylaxis of vulvovaginitis]. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
[Effect of oral <i>Lactobacillus</i> <i>rhamnosus</i> GR-1 and <i>Lactobacillus</i> <i>reuteri</i> RC-14 on vaginal Group B <i>Streptococcus</i> colonization and vaginal microbiome in late pregnancy]. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
[Efficacy of Lactobacillus Rhamnosus GR-1 and of Lactobacillus Reuteri RC-14 in the treatment and prevention of vaginoses and bacterial vaginitis relapses]. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
A Randomized Controlled Open Label Crossover Trial to Study Vaginal Colonization of Orally Administered Lactobacillus Reuteri RC-14 and Rhamnosus GR-1 in Pregnant Women at High Risk for Preterm Labor. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Cervicovaginal microbiome dynamics after taking oral probiotics. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Changes in vaginal microbiota following antimicrobial and probiotic therapy. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Effect of 25 weeks probiotic supplementation on immune function of HIV patients. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Effect of Oral Probiotic <i>Lactobacillus rhamnosus</i> GR-1 and <i>Lactobacillus</i> <i>reuteri</i> RC-14 on the Vaginal Microbiota, Cytokines and Chemokines in Pregnant Women. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Effectiveness of oral intake of <i>Lactobacillus rhamnosus GR-1</i> and <i>Lactobacillus reuteri RC-14</i> on Group B <i>Streptococcus</i> colonization during pregnancy: a midwifery-led double-blind randomized controlled pilot trial. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Effects of probiotics on the recurrence of bacterial vaginosis: a review. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Fermented rice bran prevents atopic dermatitis in DNCB-treated NC/Nga mice. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Immobilization of cadmium and lead by <i>Lactobacillus rhamnosus</i> GR-1 mitigates apical-to-basolateral heavy metal translocation in a Caco-2 model of the intestinal epithelium. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Improvement of Myelopoiesis in Cyclophosphamide-Immunosuppressed Mice by Oral Administration of Viable or Non-Viable <i>Lactobacillus</i> Strains. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Lactobacilli for prevention of urogenital infections: a review. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 to prevent or cure bacterial vaginosis among women with HIV. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Microbiota at Multiple Body Sites during Pregnancy in a Rural Tanzanian Population and Effects of Moringa-Supplemented Probiotic Yogurt. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Non-Antibiotic Prophylaxis for Urinary Tract Infections. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Nucleic acid-based diagnosis of bacterial vaginosis and improved management using probiotic lactobacilli. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 to reduce Group B Streptococcus colonization in pregnant women: A randomized controlled trial. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Oral probiotics and the female urinary microbiome: a double-blinded randomized placebo-controlled trial. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Oral probiotics can resolve urogenital infections. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Pilot assessment of probiotics for pregnant women in Rwanda. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trial. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Probiotics and the urologist. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Probiotics for the treatment of women with bacterial vaginosis. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
The influence of probiotics on genital high-risk human papilloma virus clearance and quality of cervical smear: a randomized placebo-controlled trial. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
The influence of probiotics on the cervical malignancy diagnostics quality. |
| Lactobacillus rhamnosus GR-1 |
RepHresh™ Pro-B™ Probiotic |
Vaginal & gut microbiota diversity in pregnant women with bacterial vaginosis & effect of oral probiotics: An exploratory study. |
| Lactobacillus rhamnosus LbV96 (DSM 22560) |
AZO Complete Feminine Balance |
Effect of a yoghurt drink containing Lactobacillus strains on bacterial vaginosis in women - a double-blind, randomised, controlled clinical pilot trial. |
| Lactobacillus rhamnosus LbV96 (DSM 22560) |
AZO Complete Feminine Balance |
Impact of oral administration of four <i>Lactobacillus</i> strains on Nugent score - systematic review and meta-analysis. |
| Lactobacillus rhamnosus Lcr35 |
Provacare® |
Amelioration of Chemotherapy-Induced Intestinal Mucositis by Orally Administered Probiotics in a Mouse Model. |
| Lactobacillus rhamnosus Lcr35 |
Provacare® |
Combined Effects of Lactobacillus rhamnosus and Egg Oral Immunotherapy in a Mouse Model of Egg Allergy. |
| Lactobacillus rhamnosus Lcr35 |
Provacare® |
Oral administration of Lactobacillus casei variety rhamnosus partially alleviates TMA-induced atopic dermatitis in mice through improving intestinal microbiota. |
| Lactobacillus rhamnosus Lcr35 |
Provacare® |
Oral probiotic treatment of Lactobacillus rhamnosus Lcr35(®) prevents visceral hypersensitivity to a colonic inflammation and an acute psychological stress. |
| Lactobacillus rhamnosus Lcr35 |
Provacare® |
Persistence of colonization of intestinal mucosa by a probiotic strain, Lactobacillus casei subsp. rhamnosus Lcr35, after oral consumption. |
| Lactobacillus rhamnosus Lcr35 |
Provacare® |
Vaginal impact of the oral administration of total freeze-dried culture of LCR 35 in healthy women. |
| Lactobacillus rhamnosus Lr-32 |
Custom Probiotics |
Cheese supplemented with probiotics reduced the Candida levels in denture wearers-RCT. |
| Lactobacillus rhamnosus R0011 |
Flora Pregnancy Care Probiotic |
A double blind randomized trial showing probiotics to be ineffective in acute diarrhea in Indonesian children. |
| Lactobacillus rhamnosus R0011 |
Flora Pregnancy Care Probiotic |
A double-blind placebo-controlled randomized trial on probiotics in small bowel bacterial overgrowth in children treated with omeprazole. |
| Lactobacillus rhamnosus R0011 |
Flora Pregnancy Care Probiotic |
Calcium phosphate supplementation increases faecal Lactobacillus spp. in a randomised trial of young adults. |
| Lactobacillus rhamnosus R0011 |
Flora Pregnancy Care Probiotic |
Probiotics as adjunctive treatment for chronic rhinosinusitis: a randomized controlled trial. |
| Lactobacillus rhamnosus R0011 |
Flora Pregnancy Care Probiotic |
Pulse probiotic administration induces repeated small intestinal Muc3 expression in rats. |
| Lactobacillus rhamnosus R0011 |
Flora Pregnancy Care Probiotic |
The role of luminal factors in the recovery of gastric function and behavioral changes after chronic Helicobacter pylori infection. |
| Lactobacillus salivarius HA-118 |
Human Probiotics |
Bifidobacterium longum R0175 attenuates post-myocardial infarction depressive-like behaviour in rats. |
| Lactobacillus Salivarius Ls-33 |
Custom Probiotics |
Effects of a nine-strain bacterial synbiotic compared to simethicone in colicky babies - an open-label randomised study. |
| Lactobacillus Salivarius Ls-33 |
Custom Probiotics |
Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model. |
| Lactobacillus salivarius W24 |
Ecologic® Barrier for Metabolic Health |
Effects of probiotic Lactobacillus salivarius W24 on the compositional stability of oral microbial communities. |
| Lactocaseibacillus rhamnosus ATCC 53103 |
resB® Lung Support |
Anti-cariogenic property of Carica papaya, Trachyspermum ammi, Caesalpinia crista linn extracts and their effect on human oral keratinocytes. |
| Lactocaseibacillus rhamnosus ATCC 53103 |
resB® Lung Support |
Effects of oral Akkermansia muciniphila supplementation in healthy dogs following antimicrobial administration. |
| Lactocaseibacillus rhamnosus ATCC 53103 |
resB® Lung Support |
Fecal recovery following oral administration of Lactobacillus strain GG (ATCC 53103) in gelatine capsules to healthy volunteers. |
| Lactocaseibacillus rhamnosus ATCC 53103 |
resB® Lung Support |
No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study. |
| Lactocaseibacillus rhamnosus ATCC 53103 |
resB® Lung Support |
No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study. |
| Lactocaseibacillus rhamnosus ATCC 53103 |
resB® Lung Support |
The Lepidoptera Galleria mellonella "in vivo" model: a preliminary pilot study on oral administration of Lactobacillus plantarum (now Lactiplantibacillus plantarum). |
| Lactococcus lactis JCM5805 (L. lactis plasma) |
IMMUNOFLORA |
Administration of Lactococcus lactis strain Plasma induces maturation of plasmacytoid dendritic cells and protection from rotavirus infection in suckling mice. |
| Lactococcus lactis JCM5805 (L. lactis plasma) |
IMMUNOFLORA |
Administration of plasmacytoid dendritic cell-stimulative lactic acid bacteria enhances antigen-specific immune responses. |
| Lactococcus lactis JCM5805 (L. lactis plasma) |
IMMUNOFLORA |
Administration of plasmacytoid dendritic cell-stimulative lactic acid bacteria is effective against dengue virus infection in mice. |
| Lactococcus lactis JCM5805 (L. lactis plasma) |
IMMUNOFLORA |
Effects of oral intake of plasmacytoid dendritic cells-stimulative lactic acid bacterial strain on pathogenesis of influenza-like illness and immunological response to influenza virus. |
| Lactococcus lactis JCM5805 (L. lactis plasma) |
IMMUNOFLORA |
Enhancement of immunomodulative effect of lactic acid bacteria on plasmacytoid dendritic cells with sucrose palmitate. |
| Lactococcus lactis JCM5805 (L. lactis plasma) |
IMMUNOFLORA |
Glucagon-independent renal hyperaemia and hyperfiltration after an oral protein load in Child A liver cirrhosis. |
| Lactococcus lactis JCM5805 (L. lactis plasma) |
IMMUNOFLORA |
Induction of anti-viral genes mediated by humoral factors upon stimulation with Lactococcus lactis strain plasma results in repression of dengue virus replication in vitro. |
| Lactococcus lactis JCM5805 (L. lactis plasma) |
IMMUNOFLORA |
Lactococcus lactis subsp. lactis JCM 5805 activates natural killer cells via dendritic cells. |
| Lactococcus lactis JCM5805 (L. lactis plasma) |
IMMUNOFLORA |
Long-term administration of pDC stimulative lactic acid bacteria, Lactococcus lactis strain Plasma, prevents immune-senescence and decelerates individual senescence. |
| Lactococcus lactis JCM5805 (L. lactis plasma) |
IMMUNOFLORA |
Long-term administration of pDC-Stimulative Lactococcus lactis strain decelerates senescence and prolongs the lifespan of mice. |
| Lactococcus lactis JCM5805 (L. lactis plasma) |
IMMUNOFLORA |
Oral administration of Lactococcus lactis subsp. lactis JCM5805 enhances lung immune response resulting in protection from murine parainfluenza virus infection. |
| Lactococcus lactis JCM5805 (L. lactis plasma) |
IMMUNOFLORA |
Spherical lactic acid bacteria activate plasmacytoid dendritic cells immunomodulatory function via TLR9-dependent crosstalk with myeloid dendritic cells. |
| Lactococcus lactis JCM5805 (L. lactis plasma) |
IMMUNOFLORA |
Staphylococcus aureus Epicutaneous Infection Is Suppressed by Lactococcus lactis Strain Plasma via Interleukin 17A Elicitation. |
| Lactococcus lactis JCM5805 (L. lactis plasma) |
IMMUNOFLORA |
The Effects of Plasmacytoid Dendritic Cell-Stimulative Lactic Acid Bacteria, <i>Lactococcus lactis</i> Strain Plasma, on Exercise-Induced Fatigue and Recovery via Immunomodulatory Action. |
| Lactococcus lactis JCM5805 (L. lactis plasma) |
IMMUNOFLORA |
Unexpected effect of probiotics by Lactococcus lactis subsp. lactis against colitis induced by dextran sulfate sodium in mice. |
| Limosilactobacillus reuteri SD5865 |
Natures-Way-Primadophilus-Reuteri-Pearls |
Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
[Escherichia coli Nissle 1917 as safe vehicles for intestinal immune targeted therapy--a review]. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
[Probiotic therapy of pseudomembranous colitis. Combination of intestinal lavage and oral administration of Escherichia coli]. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Amelioration of cadmium- and mercury-induced liver and kidney damage in rats by genetically engineered probiotic Escherichia coli Nissle 1917 producing pyrroloquinoline quinone with oral supplementation of citric acid. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
An engineered <i>E. coli</i> Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Antimicrobial effect of probiotic bacteriocins on Streptococcus mutans biofilm in a dynamic oral flow chamber model - an in vitro study. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Assessment of the Safety and Efficacy of an Oral Probiotic-Based Vaccine Against Aspergillus Infection in Captive-Bred Humboldt Penguins (Spheniscus humboldti). |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Augmentation of host defence against bacterial and fungal infections of mice pretreated with the non-pathogenic Escherichia coli strain Nissle 1917. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Bacteria-derived long chain fatty acid exhibits anti-inflammatory properties in colitis. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Bacterial navigation for tumor targeting and photothermally-triggered bacterial ghost transformation for spatiotemporal drug release. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Bacteriocinogeny in experimental pigs treated with indomethacin and Escherichia coli Nissle. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Beneficial effects resulting from oral administration of Escherichia coli Nissle 1917 on a chronic colitis model. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Combination Therapy of TGF-ß Blockade and Commensal-derived Probiotics Provides Enhanced Antitumor Immune Response and Tumor Suppression. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Development of a tripartite vector system for live oral immunization using a gram-negative probiotic carrier. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Doxorubicin-conjugated Escherichia coli Nissle 1917 swimmers to achieve tumor targeting and responsive drug release. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
E. coli Nissle 1917 is a safe mucosal delivery vector for a birch-grass pollen chimera to prevent allergic poly-sensitization. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Effect of antibiotic, probiotic, and human rotavirus infection on colonisation dynamics of defined commensal microbiota in a gnotobiotic pig model. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Effect of Lactobacillus casei on the Pharmacokinetics of Amiodarone in Male Wistar Rats. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Effect of orally administered probiotic E. coli strain Nissle 1917 on intestinal mucosal immune cells of healthy young pigs. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Encapsulation of Escherichia coli strain Nissle 1917 in a chitosan-alginate matrix by combining layer-by-layer assembly with CaCl<sub>2</sub> cross-linking for an effective treatment of inflammatory bowel diseases. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Escherichia coli Nissle 1917 for probiotic use in piglets: evidence for intestinal colonization. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Escherichia coli Probiotic Strain ED1a in Pigs Has a Limited Impact on the Gut Carriage of Extended-Spectrum-ß-Lactamase-Producing E. coli. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Escherichia coli strain Nissle 1917 ameliorates experimental colitis by modulating intestinal permeability, the inflammatory response and clinical signs in a faecal transplantation model. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Escherichia coli strain Nissle 1917: significant reduction of neonatal calf diarrhea. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Genotoxicity of Escherichia coli Nissle 1917 strain cannot be dissociated from its probiotic activity. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Green fluorescent protein for detection of the probiotic microorganism Escherichia coli strain Nissle 1917 (EcN) in vivo. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Impact of metal ion homeostasis of genetically modified Escherichia coli Nissle 1917 and K12 (W3110) strains on colonization properties in the murine intestinal tract. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Impact of the rpoS genotype for acid resistance patterns of pathogenic and probiotic Escherichia coli. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Influence of E. coli strain Nissle 1917 (EcN) on intestinal gas dynamics and abdominal sensation. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Interference of Bifidobacterium choerinum or Escherichia coli Nissle 1917 with Salmonella Typhimurium in gnotobiotic piglets correlates with cytokine patterns in blood and intestine. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Intestinal Anti-inflammatory Effects of Outer Membrane Vesicles from <i>Escherichia coli</i> Nissle 1917 in DSS-Experimental Colitis in Mice. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Mechanistic insight into the TH1-biased immune response to recombinant subunit vaccines delivered by probiotic bacteria-derived outer membrane vesicles. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Metabolic engineering of probiotic Escherichia coli for cytolytic therapy of tumors. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Microfluidic-based multifunctional microspheres for enhanced oral co-delivery of probiotics and postbiotics. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
No Genotoxicity Is Detectable for <i>Escherichia coli</i> Strain Nissle 1917 by Standard In Vitro and In Vivo Tests. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Oral Administration of the Probiotic Strain <i>Escherichia coli</i> Nissle 1917 Reduces Susceptibility to Neuroinflammation and Repairs Experimental Autoimmune Encephalomyelitis-Induced Intestinal Barrier Dysfunction. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Oral probiotic therapy improves motor function in a rodent model of sensorimotor stroke. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Preventive effects of Escherichia coli strain Nissle 1917 with different courses and different doses on intestinal inflammation in murine model of colitis. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Probiotic <i>Escherichia coli</i> Ameliorates Antibiotic-Associated Anxiety Responses in Mice. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Probiotic Bacteria from Human Milk Can Alleviate Oral Bovine Casein Sensitization in Juvenile Wistar Rats. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Probiotic Escherichia coli Nissle 1917 suppresses allergen-induced Th2 responses in the airways. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Prophylaxis of acute respiratory infections via improving the immune system in late preterm newborns with <i>E</i>. <i>coli</i> strain Nissle 1917: a controlled pilot trial. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Reductase-Labile Peptidic Supramolecular Hydrogels Aided in Oral Delivery of Probiotics. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Sensitivity to Escherichia coli Nissle 1917 in mice is dependent on environment and genetic background. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Split immune response after oral vaccination of mice with recombinant Escherichia coli Nissle 1917 expressing fimbrial adhesin K88. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Streptococcus salivarius K12 Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors: A Randomized Controlled Trial. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
The oral administration of Lacticaseibacillus casei Shirota alleviates acetaminophen-induced liver injury through accelerated acetaminophen metabolism via the liver-gut axis in mice. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
The probiotic E. coli strain Nissle 1917 for the treatment of collagenous colitis: first results of an open-label trial. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. |
| Mutaflor (Escherichia coli strain Nissle 1917) |
Mutaflor (Canada, Australia, Findland, Germany) |
The probiotic strain Escherichia coli Nissle 1917 prevents papain-induced respiratory barrier injury and severe allergic inflammation in mice. |
| Oxalobacter formigenes DSM 4420 |
TrueMeds |
A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. |
| Oxalobacter formigenes DSM 4420 |
TrueMeds |
Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. |
| Propionibacterium freudenreichii shermanii |
Optim Propionibacter |
Effects of orally administered viable Lactobacillus rhamnosus GG and Propionibacterium freudenreichii subsp. shermanii JS on mouse lymphocyte proliferation. |
| Propionibacterium freudenreichii shermanii |
Optim Propionibacter |
Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt, or cheese. |
| Saccharomyces boulardii CNCM I-745 |
Florastor® |
Diversity of <i>Saccharomyces boulardii</i> CNCM I-745 mechanisms of action against intestinal infections. |
| Saccharomyces boulardii CNCM I-745 |
Florastor® |
Of bowels, brain and behavior: A role for the gut microbiota in psychiatric comorbidities in irritable bowel syndrome. |
| Saccharomyces boulardii CNCM I-745 |
Florastor® |
Oral Administration of Recombinant <i>Saccharomyces boulardii</i> Expressing Ovalbumin-CPE Fusion Protein Induces Antibody Response in Mice. |
| Saccharomyces boulardii CNCM I-745 |
Florastor® |
Probiotic Saccharomyces boulardii CNCM I-745 prevents outbreak-associated Clostridium difficile-associated cecal inflammation in hamsters. |
| Saccharomyces boulardii CNCM I-745 |
Florastor® |
Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. |
| Saccharomyces boulardii CNCM I-745 |
Florastor® |
Retrospective analysis of EMR database to assess the effectiveness of <i>Saccharomyces boulardii</i> CNCM I-745 in children with acute diarrhoea during routine clinical practice. |
| Saccharomyces boulardii CNCM I-745 |
Florastor® |
Saccharomyces boulardii CNCM I-745 probiotic does not alter the pharmacokinetics of amoxicillin. |
| Saccharomyces boulardii CNCM I-745 |
Florastor® |
Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea. |
| Saccharomyces boulardii CNCM I-745 |
Florastor® |
Time Series Analysis of the Microbiota of Children Suffering From Acute Infectious Diarrhea and Their Recovery After Treatment. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
A concerted probiotic activity to inhibit periodontitis-associated bacteria. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
A possible probiotic (S. salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SAR S-CoV-2. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
A TaqMan™-based quantitative PCR screening assay for the probiotic Streptococcus salivarius K12 based on the specific detection of its megaplasmid-associated salivaricin B locus. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Alteration of Streptococcus salivarius in Buccal Mucosa of Oral Lichen Planus and Controlled Clinical Trial in OLP Treatment. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Antimicrobial activity of Streptococcus salivarius K12 on bacteria involved in oral malodour. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Antimicrobial and Antibiofilm Activity of the Probiotic Strain Streptococcus salivarius K12 against Oral Potential Pathogens. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Assessment of Efficacy of BLIS-Producing Probiotic K12 for the Prevention of Group A Streptococcus Pharyngitis: a Short Communication. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
B7-H1 and B7-DC receptors of oral squamous carcinoma cells are upregulated by Porphyromonas gingivalis. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Characterization of Streptococcus salivarius growth and maintenance in artificial saliva. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Detection and Specific Enumeration of Multi-Strain Probiotics in the Lumen Contents and Mucus Layers of the Rat Intestine After Oral Administration. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Developing oral probiotics from Streptococcus salivarius. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Effect of Oral Probiotic Streptococcus salivarius K12 on Group A Streptococcus Pharyngitis: A Pragmatic Trial in Schools. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Effect of Streptococcus salivarius K12 on the in vitro growth of Candida albicans and its protective effect in an oral candidiasis model. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Effects of Streptococcus salivarius K12 with nystatin on oral candidiasis-RCT. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Extended Safety Data for the Oral Cavity Probiotic Streptococcus salivarius K12. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Genome sequence of the lantibiotic bacteriocin producer Streptococcus salivarius strain K12. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Heritability of oral microbial species in caries-active and caries-free twins. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Human Systemic Immune Response to Ingestion of the Oral Probiotic Streptococcus salivarius BLIS K12. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Impact of Chlorhexidine Pretreatment Followed by Probiotic Streptococcus salivarius Strain K12 on Halitosis in Children: A Randomised Controlled Clinical Trial. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Impact of Streptococcus salivarius K12 on Nasopharyngeal and Saliva Microbiome: A Randomized Controlled Trial. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Improvement of Psoriasis Using Oral Probiotic Streptococcus salivarius K-12: a Case-Control 24-Month Longitudinal Study. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
In vitro Interactions between <i>Streptococcus intermedius</i> and <i>Streptococcus salivarius</i> K12 on a Titanium Cylindrical Surface. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Influence of Oral Probiotic Streptococcus salivarius K12 on Ear and Oral Cavity Health in Humans: Systematic Review. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Inhibitory effect of Streptococcus salivarius K12 and M18 on halitosis in vitro. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Interferon Gamma Response in Human Saliva Following Exposure to the Oral Probiotic Streptococcus salivarius BLIS K12. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Lyophilized cell-free supernatants of the oral probiotics Streptococcus salivarius M18 and Streptococcus salivarius K12 show promises for milk safety. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Megaplasmids encode differing combinations of lantibiotics in Streptococcus salivarius. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Metabolism of L-selenomethionine and selenite by probiotic bacteria: in vitro and in vivo studies. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Mitigation of the Toxic Effects of Periodontal Pathogens by Candidate Probiotics in Oral Keratinocytes, and in an Invertebrate Model. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Multi-Strain Probiotic Supplementation with a Product Containing Human-Native S. salivarius K12 in Healthy Adults Increases Oral S. salivarius. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Oral bacteria as potential probiotics for the pharyngeal mucosa. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Oral use of Streptococcus salivarius K12 in children with secretory otitis media: preliminary results of a pilot, uncontrolled study. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Pilot study to explore the prophylactic efficacy of oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngo-tonsillar episodes in pediatric patients. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Positive clinical outcomes derived from using <i>Streptococcus salivarius</i> K12 to prevent streptococcal pharyngotonsillitis in children: a pilot investigation. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Probiotic Streptococcus salivarius K12 Alleviates Radiation-Induced Oral Mucositis in Mice. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Safety assessment of Streptococcus salivarius M18 a probiotic for oral health. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Salivary enzymes and exhaled air affect Streptococcus salivarius growth and physiological state in complemented artificial saliva. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Streptococcal Bacteriocin-Like Inhibitory Substances: Some Personal Insights into the Bacteriocin-Like Activities Produced by Streptococci Good and Bad. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Streptococcus salivarius inhibits immune activation by periodontal disease pathogens. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Streptococcus salivarius K12 Limits Group B Streptococcus Vaginal Colonization. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
The Effect of Oral Probiotics (Streptococcus Salivarius k12) on the Salivary Level of Secretory Immunoglobulin A, Salivation Rate, and Oral Biofilm: A Pilot Randomized Clinical Trial. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
The Effect of Streptococcus salivarius K12 on Halitosis: a Double-Blind, Randomized, Placebo-Controlled Trial. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
The influence of probiotic treatment on sulfasalazine metabolism in rat. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
The Selective Interaction of <i>Pistacia lentiscus</i> Oil vs. Human Streptococci, an Old Functional Food Revisited with New Tools. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. |
| Streptococcus salivarius K12 |
BLIS ThroatHealth Oral Probiotics |
Use of Streptococcus salivarius K12 to reduce the incidence of pharyngo-tonsillitis and acute otitis media in children: a retrospective analysis in not-recurrent pediatric subjects. |
| Symbioflor 2 |
German Apotheke by Paul's Mart |
Escherichia coli as a probiotic? |
| Symbioflor 2 |
German Apotheke by Paul's Mart |
Local application of bacteria improves safety of Salmonella -mediated tumor therapy and retains advantages of systemic infection. |
| VSL3 / Visbiome / De Simone Formulation |
Alfasigma USA, Inc. |
[The role of oral probiotic for bacterial vaginosis in pregnant women. A pilot study]. |
| VSL3 / Visbiome / De Simone Formulation |
Alfasigma USA, Inc. |
DNA from probiotic bacteria modulates murine and human epithelial and immune function. |
| VSL3 / Visbiome / De Simone Formulation |
Alfasigma USA, Inc. |
Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques. |
| VSL3 / Visbiome / De Simone Formulation |
Alfasigma USA, Inc. |
Investigation of probiotics in multiple sclerosis. |
| VSL3 / Visbiome / De Simone Formulation |
Alfasigma USA, Inc. |
Medical therapy for induction and maintenance of remission in pouchitis: a systematic review. |
| VSL3 / Visbiome / De Simone Formulation |
Alfasigma USA, Inc. |
PCR detection of Bifidobacterium strains and Streptococcus thermophilus in feces of human subjects after oral bacteriotherapy and yogurt consumption. |
| VSL3 / Visbiome / De Simone Formulation |
Alfasigma USA, Inc. |
Pharmacotherapy for inducing and maintaining remission in pouchitis. |
| VSL3 / Visbiome / De Simone Formulation |
Alfasigma USA, Inc. |
The role of nutrition in diarrhoea syndromes. |